ACTAUNIVERSITATIS

UPSALIENSISUPPSALA

2013

Digital Comprehensive Summaries of Uppsala Dissertationsfrom the Faculty of Medicine 919

The Immunopathology ofRheumatoid Arthritis andLeishmania donovani Infection inSudan

AMIR I. ELSHAFIE

ISSN 1651-6206ISBN 978-91-554-8710-2urn:nbn:se:uu:diva-204392

Dissertation presented at Uppsala University to be publicly examined in Rudbecksalen,Dept of Immunology, Uppsala University Rudbeck Laboratory, 751 85 Uppsala, Uppsala,Wednesday, September 18, 2013 at 09:15 for the degree of Doctor of Philosophy (Faculty ofMedicine). The examination will be conducted in English.

AbstractElshafie, A. I. 2013. The Immunopathology of Rheumatoid Arthritis and Leishmaniadonovani Infection in Sudan. Acta Universitatis Upsaliensis. Digital ComprehensiveSummaries of Uppsala Dissertations from the Faculty of Medicine 919. 59 pp. uppsala.ISBN 978-91-554-8710-2.

Immune complexes (IC) and antibody production against self-antigens play a pathological keyrole in the development of autoimmunity that occurs in patients with parasitic infections andrheumatic diseases. My studies have targeted two groups of patients from Sudan; patients withvisceral leishmaniasis (VL) and patients with rheumatoid arthritis (RA).

In VL patients I studied the functional role of IC and IC-induced cytokine production in thepathogenesis of the disease and their effect on kidney functions. For the Sudanese RA cohort, Iperformed a comparative study with Swedish RA patients. I also investigated the Sudanese RAcohort for the occurrence of RA-associated autoantibodies (rheumatoid factor (RF) and anti-citrullinated protein/peptide antibodies (ACPA)) and the diagnostic and prognostic impact ofthese autoantibodies on the clinical outcome.

In the VL project, I demonstrated that Sudanese VL patients had elevated serum levels of ICand of IC-induced cytokine levels in vitro. GM-CSF levels were increased in acute VL patientsand in VL patients with ongoing sodium stibogluconate treatment, and the only cytokine thatcorrelated to a high degree with circulating IC levels. Cystatin C was shown to be a superiormarker of glomerular function as compared to serum creatinine in VL patients. For the RAproject, a comparative study was performed in collaboration with the rheumatology unit at Gävlehospital. We concluded that the clinical picture of RA in Sudan was more severe, with morewidespread joint involvement and stronger laboratory signs of inflammation when compared tothe Swedish RA patients.

ACPA and RF are both included in the new 2010 RA classification criteria. In many RAstudies over the world the occurrence of ACPA and RF varies considerably, this may be dueto both geographical differences and lack of standardization for RF and anti-CCP in the RAcriteria. But in this study we aligned all antibodies to the same diagnostic specificity compared toSudanese healthy controls. When doing so we determined that IgA RF had the highest diagnosticsensitivity, a finding that differs from Caucasian studies in which IgM RF predominates. IgGRF was also the autoantibody most strongly associated with early age of disease onset and handdeformities, a clinical picture that differs in most Caucasian studies in which ACPA are thestrongest markers for bad prognosis. Thus data from this Sudanese RA cohort implies significantclinical and immunological differences compared to Caucasian RA patients.

Amir I. Elshafie, Uppsala University, Department of Immunology, Genetics and Pathology,Clinical Immunology, Rudbecklaboratoriet, SE-751 85 Uppsala, Sweden.

© Amir I. Elshafie 2013

ISSN 1651-6206ISBN 978-91-554-8710-2urn:nbn:se:uu:diva-204392 (http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-204392)

الله الرحمن الرحيمبسم

To the soul of my father Ibrahim Elshafie!

List of Papers

This thesis is based on the following papers, which are referred to in the text by their Roman numerals.

1. Elshafie AI*, Åhlin E*, Mathsson L, ElGhazali G, Rönnelid J. Cir-culating immune complexes (IC) and IC-induced levels of GM-CSF are increased in Sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. J Immunol. 2007 Apr 15;178(8):5383-9.

2. Elshafie AI, Elghazali G, Rönnelid J, Venge P. Cystatin C as a marker of immune complex associated renal impairment in a Suda-nese population with visceral leishmaniasis. Am J Trop Med Hyg. 2006 Nov; 75(5): 864-8.

3. Elshafie AI, Elkhalifa AD, Nourein S, Aledrissy MIA, Elagib EM, Nur MAM, Weitoft T and Rönnelid J. Disease severity of Rheuma-toid Arthritis in Sudan: Comparative study between Sudan and Swe-den. Manuscript

4. Elshafie AI, Nourein S, Aledrissy MIA, Elagib EM, Nur MAM and Rönnelid J. Diagnostic and prognostic utility of anti-CCP and RF isotopes in Sudanese patients with rheumatoid arthritis. Manuscript

*Authors contributed equally.

Reprints were made with permission from the respective publishers.

Contents

Abstract ........................................................................................................... ii

List of Papers .................................................................................................. v

Abbreviations ................................................................................................. ix

Introduction ................................................................................................... 11Leishmania donovani infection ................................................................ 11

Leishmania life cycle ........................................................................... 11The clinical picture of VL ................................................................... 12IC and cytokines induction in VL: ...................................................... 13Cystatin C ............................................................................................ 14

Rheumatoid Arthritis ................................................................................ 15Introduction ......................................................................................... 15The pathology of rheumatoid arthritis ................................................. 15The clinical features and classification criteria of RA ........................ 16Autoantibodies in RA .......................................................................... 17Rheumatoid arthritis in Africa ............................................................. 19Rheumatoid arthritis treatment ............................................................ 20Environmental factors and Rheumatoid arthritis ................................. 21

Materials and Methods ................................................................................. 22Study area, patients and establishment of VL diagnosis .......................... 22Study area, patients and establishment of RA diagnosis ......................... 23Sample collection and transport to Sweden ............................................. 24

The VL project: ................................................................................... 24The RA project: ................................................................................... 25

Polyethylene glycol precipitation of IC ................................................... 25Preparation of mononuclear cells and cell cultures ................................. 26Measurement of cytokines in supernatants .............................................. 26FcγR blocking experiments: ..................................................................... 27C1q-binding assay for circulating IC ....................................................... 27Biochemical markers of kidney and liver functions ................................ 27Autoantibody measurements .................................................................... 27Ethical approvals ...................................................................................... 28

Sudan ................................................................................................... 28Sweden ................................................................................................ 28

Statistics: .................................................................................................. 29Paper 1 ................................................................................................. 29Papers 1, 2 and 3 .................................................................................. 29

Aims of the study .......................................................................................... 30Paper 1: .................................................................................................... 30Paper 2 ...................................................................................................... 30Paper 3 ...................................................................................................... 30Paper 4 ...................................................................................................... 30

Results and Discussions ................................................................................ 31Paper 1 ...................................................................................................... 31Paper 2 ...................................................................................................... 32Paper 3 ...................................................................................................... 33Paper 4 ...................................................................................................... 36

Future perspective ......................................................................................... 40Visceral Leishmaniasis in Sudan ............................................................. 40Rheumatic diseases in Sudan ................................................................... 40

Rheumatoid arthritis ............................................................................ 41Systemic lupus erythematous .............................................................. 41

Acknowledgments ........................................................................................ 42

References ..................................................................................................... 44

Abbreviations

ACR American College of Rheumatology ACPA Anti-citrullinated proten/peptide antibodies ANOVA Analysis of variance Anti-TNFα Antibody to tumor necrosis factor alpha Anti-CCP Anti-cyclic citrullinated peptide/protein Anti-FcγRII, RIII Anti-Fc gamma receptor II, III AU Arbitrary units AUC Area under the curve BD Boutonniere deformity CD Cluster of differentiation DMARD Disease-modifying anti-rheumatic drugs ELISA Enzyme-linked immunosorbent assay EULAR European League against Rheumatism EDTA Ethylenediaminetetraacetic acid HEPES Hydroxyethyl piperazineethanesulfonic acid GFR Glomerular filtration rate GM-CSF Granulocyte macrophage-colony stimulating factor HLA DRB1 SE Human leucocyte antigen DRB1 shared epitope IC Immune complexes IU International unit IFN-γ Interferon gamma IL Interleukin IL-1ra Interleukin-1 receptor antagonist KD Kilodalton LD Leishmania donovani LPS Lipopolysaccharide PBMC Peripheral blood mononuclear cells PEG Polyethylene glycol PKDL Post kala-azar dermal leishmaniasis RA Rheumatoid arthritis RF Rheumatoid factor ROC Receiver operator characteristics RPMI Roswell Park Memorial Institute SND Swan neck deformity Th T helper cell TNFα Tumor necrosis factor alpha

TNF-Rp75 Tumor necrosis factor receptor p75 UD Ulnar deviation VL Visceral leishmaniasis ZD Z deformity PEST Penicillin-streptomycin

11

Introduction

Leishmania donovani infection

Leishmania donovani (LD) infection is a disease of public health importance in Sudan and many other tropical countries and is considered to be one of the main health foci in east Africa (1). LD infection is a disease caused by pro-tozoa of the Leishmania donovani complex (L. donovani, L. archibaldi, and L. infantum/chagasi). Leishmania, which are introduced into their human hosts by sandflies, rapidly invade macrophages, where they multiply inside phagolysosomes. Human infections may be asymptomatic (sub-clinical) or may cause a severe visceral disease that is called visceral leishmaniasis (VL) or kala-azar (2-5). The geographical map of VL is gradually changing in Sudan. This may be partly related to the geopolitical and social mass move-ment of the Sudanese people and partly by the slow spread of the disease to occupy areas not previously known to harbor it (6).

The known endemic areas of VL are the south-eastern borders of Sudan covering an area of about 120 sq. kilometers along the Sudanese-Ethiopian border extending from Kassala in the Far East down to Kapoeta in the South. These areas are savannah and sub-Saharan, characterized by the presence of scattered shrubs of acacia trees punctuated with termite hills, a good habitat for the Phlebotomus fly (7).

Leishmania life cycle

Leishmania spp. are transmitted by the bite of female Phlebotomus sandflies. The sandflies inject the infective stage, metacyclic promastigotes, during blood meals (8). During its life cycle the Leishmania parasite alternates be-tween two distinct developmental stages. In the mammalian host, the para-site exists as the non-motile amastigote form, which proliferates within the acidic and hydrolase-rich phagolysosomal compartment of host macrophages (9). Transmission of the parasite is mediated by the blood-sucking sandfly, of either the genus Phlebotomus (in the Old World) or the genus Lutzomyia (in the New World). When feeding on an infected mammal, the sandfly takes up amastigote-containing macrophages/monocytes. During digestion of the bloodmeal, amastigotes initiate their differentiation into the motile pro-mastigote form, which will attach to the midgut epithelium to avoid being excreted together with the digested blood meal. Virulence is acquired during

12

metacyclogenesis, a process by which dividing, non-infective promastigotes (procyclic) transform into a non-dividing infective form (10). These metacy-clic promastigotes detach from the gut epithelial cells and migrate towards the anterior end of the digestive tract. Upon the next blood meal, metacyclic promastigotes are inoculated into the mammalian host, where they must successfully evade and resist non-specific defense mechanisms such as com-plement-mediated lysis, to ultimately bind and enter mononuclear phago-cytes by a receptor-mediated process. Once inside a parasitophorous vacuole or phagosome, metacyclic promastigotes avoid degradation and establish conditions favorable to their proliferation. The increased temperature and the decreased phagosomal pH provide the signals required for the differentiation from promastigotes to amastigotes (11). Ultimately, infected macrophages rupture, releasing the amastigotes into the surrounding environment where they can infect neighboring macrophages (Figure 1).

The socioeconomic situation is the most important factor governing the spread of this disease especially among nomadic cattle raisers, who search for water and grass for their cattle. Recently, the civil war has promoted the spread of the disease by forcing many tribes in the endemic area to move northward. This situation brought the disease with them to the vicinity of Khartoum state and the loss of cattle and other domestic animals upon which the sandflies feed has forced the Leishmania parasite to shift to humans in-stead (12, 13).

The clinical picture of VL

The clinical picture of VL includes recurrent fever, hepatosplenomegaly, general lymphadenopathy, pancytopenia, and anemia. Death occurs in the absence of appropriate chemotherapy (14). Post-kala-azar dermal leishmani-asis (PKDL) is a complication of VL and is characterized by a macular, maculopapular, and nodular rash in patients who have recovered from VL and who are otherwise well. The rash usually starts around the mouth, from where it spreads to other parts of the body depending on severity. PKDL is mainly evident in Sudan and India, where it appears in 50% and 5–10% of treated VL cases, respectively (15). The interval after therapy at which PKDL follows VL is 0–6 months in Sudan and 2–3 years in India (15). No firm evidence exists that predict which VL patients will develop PKDL, but an interesting finding is the high expression of interleukin (IL)-10 in VL patients subsequently developing PKDL after Leishmania therapy (16). This might be due to differences in the host immune response against the parasite itself or the response to treatment or both. Polymorphisms in genes control-ling innate and adaptive immunity have been suggested as possible candi-dates for PKDL development (17).

13

Figure 1. Leishmaniasis is transmitted by the bite of infected female phlebotomine

sandflies. The sandflies inject the infective stage (promastigotes) from their probos-

cis during blood meals (1). Promastigotes that reach the puncture wound are phago-

cytosed by macrophages (2) and other types of mononuclear phagocytic cells. Pro-

mastigotes transform in these cells into the tissue stage of the parasite (amastigotes)

(3), which multiply by simple division and proceed to infect other mononuclear

phagocytic cells (4). The parasite, the host, and other factors affect whether the in-

fection becomes symptomatic and whether cutaneous or visceral leishmaniasis en-

sues. Sandflies become infected by ingesting infected cells during blood meals (5,

6). In sandflies, amastigotes transform into promastigotes, develop in the gut (7) and

migrate to the proboscis (8). Figure 1 reproduced with permission from

www.dpd.cdc.gov.

IC and cytokines induction in VL:

Leishmania is an obligate intracellular parasite of macrophages. Studies have demonstrated that specific immunity in VL is mediated by CD4 T helper (Th) cells and that disease susceptibility is associated with the inability to produce a macrophage-stimulating cytokine profile (Th1 profile) including interferon-γ (IFN-γ), IL-2, and IL-12. Conversely, an elevated production of immunosuppressive cytokines such as IL-10 and IL-4 (Th2 profile), as well as high levels of tumor necrosis factor-α (TNFα), may be associated with susceptibility (18, 19).

14

The hemopoietic growth factor granulocyte macrophage-colony stimulat-ing factor (GM-CSF) has many stimulatory effects on mono-cytes/macrophages that has beneficial effects during intracellular infections, such as enhancing phagocytic and metabolic functions and the release of other proinflammatory cytokines (20). Addition of GM-CSF to human mon-ocytes in vitro increases their leishmanicidal effects (21). When mice infect-ed with L. donovani were treated with murine GM-CSF they showed in-creased leishmanicidal activity, as well as leukocytosis and myelomonocytic accumulation of myelomonocytic cells in infected viscera (22). In a small placebo controlled study, GM-CSF-treated Leishmania chagasi-infected patients had a significantly reduced number of secondary infections, along with increased neutrophil counts (23). The production of GM-CSF was in-creased during infection in the liver of L. donovani-infected BALB/c mice (22) and in mouse bone marrow stromal macrophages (24), findings arguing for the potentially disease-limiting effect of Leishmania infection-induced GM-CSF production. This hypothesis is also sustained by the fact that Leishmania parasites genetically engineered to produce GM-CSF within their phagosomes exhibited poor survival within macrophages that had been activated by GM-CSF to produce an array of pro-inflammatory cytokines (25). Recently, L. donovani amastigote antigens have been reported to in-duce GM-CSF production in mouse peritoneal macrophages both in vitro and in vivo (26).

Leishmania-infected patients have increased levels of circulating Clq-binding immune complexes (IC) (27-32) that contain Leishmania antigens (33, 34).

Cystatin C During infection with Leishmania spp. various host organs are affected, in-cluding the liver, spleen, and kidney. VL-related nephropathy is known both in humans and animals and was identified by the presence of hematuria and proteinuria, but also in some cases by rising serum creatinine or urea levels (35-40). As markers of kidney function, creatinine and urea levels are both confounded by several unrelated factors, which may seriously hamper the detection of any reduction in glomerular filtration rate. Serum creatinine levels are dependent on muscle mass (41) and urea is dependent on diet and diuresis (42). With the introduction of cystatin C, an accurate and sensitive way to estimate glomerular filtration rate (GFR) has become available, which is unaffected by factors that influence creatinine and urea levels (43-46).

Cystatin C is a low-molecular-weight protein of 13 kD produced by all nucleated cells. It is freely filtered by the glomerulus, reabsorbed, and catab-olized, but it is not secreted in the tubules (47). The production of cystatin C is regulated genetically and it is independent of extra-renal factors such as

15

environmental changes or disease activity (48). Studies have demonstrated the superiority of serum cystatin C compared to serum creatinine in detecting minor GFR reductions (49). The main advantage of cystatin C compared to serum creatinine as a GFR marker is that cystatin C is less dependent upon the body composition than serum creatinine (41). Cystatin C is a promising, easily measurable (50), effective and an earlier surrogate marker of de-creased renal function than serum creatinine (51, 52).

The mechanisms underlying renal involvement in VL patients may be many, but the involvement of IC and their deposition in the kidney has been described to be involved in the pathogenesis of leishmaniasis (53, 54). IC might also affect disease progression and disease outcome through induction of pro- or anti-inflammatory cytokines like IL-10, GM-CSF and TNF-α (55, 56).

Rheumatoid Arthritis

Introduction

Rheumatoid arthritis (RA) is a chronic multisystem inflammatory progres-sive disease of unknown etiology that leads to pain, stiffness and physical disability, and can result in joint destruction, especially if the diagnosis and early treatment with disease-modifying anti-rheumatic drugs (DMARD) or biologically engineered macromolecules are delayed (57-59).

The pathology of rheumatoid arthritis

RA is an autoimmune disease and until now the initial triggering mecha-nisms underlying disease development are not well understood (60). It has been demonstrated that several types of cells from both the innate and adap-tive immune systems actively participate and form complex networks of cell–cell interactions that contribute to the development and chronicity of RA synovitis, and destruction of cartilage and bone destruction (61).

RA pathogenesis seems to involve a number of humoral and cellular im-mune processes (62) as well as IC production and complement activation (63, 64). The cellular mechanisms leading to RA pathology involves mono-cyte-derived cytokines, lymphocytes (65), neutrophils and Th17 cells (66), and the humoral mechanisms involve B cells and antibodies (67). Another mechanism that could also worsen or lead to RA development is hypoxia, due to its direct link to inflammation and angiogenesis in the affected joints (68).

Nowadays, several lines of evidence stress to the role of B cells as a criti-cal factor for RA development. In RA, B cells start to produce a variety of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated pro-

16

tein/peptide antibodies (ACPA), that subsequently form IC that deposit in the joints, resulting in complement activation and subsequent inflammation (67). In addition, patients with early RA were shown to have a disturbance in memory B cell circulation (69) with increased cytokine production in rela-tion to B cell activation and survival (66, 70). B cells also play an important role in the process of antigen presentation and T cell activation, cytokine release, and ectopic lymphoid organogenesis (67).

Environmental factors, especially cigarette smoking and other pulmonary exposure (e.g. silica), in association with susceptibility genes are thought to drive the processes towards autoimmunity and inflammation apparent in RA (71, 72). Recent reports confirm the interplay between genetic and environ-mental factors and the process of protein citrullination as a key mechanism underlying RA development (60, 73).

The pathology of RA starts when the immune system of the host is trig-gered; cells of the immune system will produce autoantibodies and inflam-matory cytokines, creating a cascade of inflammation resulting in pannus formation. Pannus is a soft tissue that expands on the cartilage surface and invades the underlying bone matrix. The leading edge of pannus is com-posed of fibroblast- and macrophage-like cells, which produce proteinases able to cause destruction of articular cartilage (74). Additional joint damage and systemic complications ensue, resulting from a complex process of in-flammatory mediators being released in the affected joints (71).

The clinical features and classification criteria of RA

The clinical presentation of RA often starts insidiously but can also be epi-sodic or acute. It is usually presented as a polyarthritis affecting small joints or a combination of small and large joints. Early disease is characterized by pain and other cardinal signs of inflammation (e.g. heat, swelling, functional loss due to inflammation, and possible erythema over the joints), but not by damage and deformity. If the disease remains active and uncontrolled the inflammation will usually spread to additional joints and gradual irreversible tissue damage will occur, causing deformity and instability of joints. One of the serious long-term disabilities is associated with damage to the larger weight bearing joints (75).

Inflammation of other synovial structures is common in RA and a similar process may occur in tendon sheaths, progressing to serious dysfunction and rupture. The typical RA deformities include ulnar deviation (UD) of the fin-gers, z deformity (ZD) of the thumb, swan neck deformity (SND) and bou-tonniere deformity (BD) that occur due to damage or displacement of ten-dons (75).

The standard for defining RA patients in the clinics is based on classifi-cation criteria. In 1987 the American Rheumatism Association, later named the American College of Rheumatology (ACR) developed classification

17

criteria (76) for RA diagnosis, but this set of criteria has some limitations, especially in describing patients with early RA. They are therefore not opti-mal in identifying early patients who would benefit from prompt effective treatment. Consequently, in 2010 a joint working group of the ACR and the European League Against Rheumatism (EULAR) developed new RA classi-fication criteria (77) with specific emphasis on identifying patients with a relatively short duration of symptoms who may benefit from early institution of DMARD therapy that can prevent or delay the poor outcome of the dis-ease. The 2010 ACR/EULAR classification criteria are specifically intended to be used before erosions become detectable on X-rays. They include four scored domains: symptom duration (< or >6 weeks), number and type of joints involved, biomarkers of inflammation (ESR and CRP), and bi-omarkers of specific autoimmunity (RF and ACPA). Only patients with at least 6 points (out of 10 possible) are classified as having RA (77).

Autoantibodies in RA

RA has been associated with several autoantibodies (78) and the ones most used in clinical diagnosis are RF and ACPA, with antibodies against cyclic citrullinated peptide (anti-CCP) version 2 being the most commonly used commercial test. After the discovery of ACPA both RF and ACPA were proposed to be used for the diagnosis of RA patients (79), and were both included as serological markers in the new ACR/EULAR classification crite-ria (77).

Rheumatoid factor (RF)

RF had been the best described RA-associated serological marker for a long time (80) and was included in the 1987 ACR classification criteria (76). RF was firstly described by Erik Waaler in 1940 (80) and was then hypothesized to be a pathogenic autoantibody with a key role in the physiopathology of RA (81). RF is an antibody that directly bind to the Fc portion of the normal human IgG and are locally produced by B cells in the lymphoid follicles and the germinal center-like structures that develop in the inflamed synovium (82). These autoantibodies are of different immunoglobulin isotypes (IgM, IgG, or IgA) and IgM RF is usually measured in RA patients and can be detected in 60–80 % of the patients (83). In Caucasian RA patients the oc-currence of IgA and IgG RF was shown to be lower than of IgM RF (84, 85).

RF has been observed in many other autoimmune diseases, including sys-temic lupus erythematous (SLE), as well as in non-autoimmune conditions, such as chronic infections, and also in healthy individuals (67). Nevertheless, RF from healthy subjects is of IgM class, polyreactive and with low affinity (86), whereas RF from RA patients belongs to all isotypes and exhibit affini-ty maturation (87).

18

Anti-cyclic citrulinated protein/peptide antibodies (ACPA)

ACPA were firstly described by Schellekens et al. (88) in 1998 and then confirmed by another group (89). According to a meta-analysis, these auto-antibodies occur in 67% of RA patients (90), whereas another meta-analysis reports ACPA sensitivities between 39-94% (91). ACPA analyses have high disease specificity (90–98 %); this means that ACPA are rarely present in other diseases or in healthy individuals (92, 93). These autoantibodies rec-ognize peptides or proteins containing citrulline, a non-standard amino acid. This peptide-bound citrulline is generated by the post-translational modifica-tion of arginine residues by peptidylarginine deiminase enzymes (94), in a process known as citrullination or deimination. The process of protein citrul-lination is a common phenomenon that occurs in normal situations like in-flammation, apoptosis, or keratinization. In RA, ACPA are locally produced in RA joints, where proteins are citrullinated during the inflammatory pro-cess (95) and this citrullination can affect a number of proteins such as fil-aggrin, fibrin and vimentin as well as nuclear and stress proteins (96). How-ever, the major citrullinated protein in RA joints was determined to be fibrin (97).

Histologically, ACPA-positive patients have more infiltrating lympho-cytes in synovial tissue, whereas ACPA negative patients have more fibrosis and increased thickness of the synovial lining layer (98). Importantly, ACPA not only have a better diagnostic value than RF in terms of specificity but also seem to be better predictors of poor prognostic features such as progres-sive joint destruction (90, 99, 100).

The role of ACPA/anti-CCP and RF in RA diagnosis

The diagnostic utility for RF was discovered to be suboptimal, since it has a variable sensitivity (54-88%) and lower specificity than ACPA, especially when compared with clinically relevant disease control groups (48-92%) (92, 101-104). ACPA are found to be highly specific for RA (88, 90, 104-106) and have the potential to predict development of RA in patients with early arthritis not yet fulfilling RA criteria (91, 107, 108).

The use of combined serological screening tests could help in the diagno-sis of RA. A study by Raza et al. reported that in patients with early symp-toms (<3 months) of synovitis, the combined occurrence of both RF and anti-CCP increased the specificity for RA development as compared to the occurrence of only one of the autoantibodies (109). In addition, Bas et al. showed that combining tests for anti-CCP, IgA and IgM RF would increase test specificity from 82% to 98% but with decreased sensitivity (41%) when compared to anti-CCP alone (68%) (110). Another report by Jonsson et al. showed that simultaneous elevation for both IgM and IgA RF has very high diagnostic specificity and positive predictive value for RA (111).

19

RF isotypes and treatment

IgG RF was determined to be a good predictive marker for treatment re-sponse when using B cell depleting therapy (112, 113). This is in agreement with the long-term conception that IgG RF is the main driver of autoimmune rheumatoid inflammation through production of TNFα and IL-1 (114) and its role in driving persistent RA inflammation (115). High pre-treatment levels of IgA RF were associated with poor clinical response to anti-TNFα drugs (116). It was also shown that efficient response to Rituximab treatment was only related to those patients with RF (117, 118); these studies looked only for IgM RF but not for the other RF isotypes.

RF isotypes and RA prognosis

In RA the presence of autoantibodies (RF and/or ACPA) are associated with poor prognosis such as the presence of bone erosions and extra-articular manifestations (119, 120). Patients with raised IgG RF and IgA RF in partic-ular have progressive joint damage and extra-articular manifestations (121). The presence of IgA RF associates with poor clinical outcome and poor re-sponse to treatment. In a study performed by Can et al. increased levels of IgA RF associated with severe disease and extra-articular manifestations (122), and other reports have also shown that IgA RF may be strongly linked to more severe disease (123-125). Poor clinical responses to anti-TNFα drugs were also found to occur in patients with higher pretreatment levels of IgA RF (116).

Many studies had investigated the relationship between disease activity and RF isotypes. Pop et al. reported that only IgG RF levels but not IgM RF levels correlated well with disease activity (126), and Silvestris et al. report-ed that IgG RF and IgA RF levels correlated better with disease activity than did the level of IgM RF (127). In addition, an increased IgG RF level was reported to be significantly related to the occurrence of subcutaneous nod-ules (128). A study from Iceland also demonstrated that extra-articular mani-festations were predominantly associated with raised IgA RF (129).

RF isotypes have a connection to RA mortality, patients with IgA and IgM RF isotypes having a higher risk for dying earlier than patients without these RF isotypes (130). No such association was determined for IgG RF.

Rheumatoid arthritis in Africa

To date the exact prevalence of RA in Africa is not well studied. One reason might be that reports from different parts of Africa have used different RA criteria for diagnosis (131, 132); another reason might be that the age struc-ture differs considerably between different areas (133). Some papers have reported the disease prevalence in Africa to be lower than in Europe (132, 134, 135), others claim that the disease is increasing (136-140). Kalla et al.

20

postulated that this variation could be related to urbanization and the change in lifestyle in modern Africa (141). There are no scientific publications about the prevalence or the severity of RA in modern Sudan. I have only found one case report describing the evidence of RA lytic lesions in a Nubian female mummy from around 3000 years ago (142).

Reports from different parts of Africa have alluded to varying RA disease severity; however, none of these reports have actually been truly compara-tive between different parts of the continent (135-138, 140, 141, 143, 144). For example Malemba et el. argued that the disease severity (investigated as the occurrence of deformities, the presence of rheumatoid nodules and radio-logical erosions) in Congolese RA patients was less severe than in Western countries (137), whereas a study in Nigeria found that the disease was severe and more than 29% of their patients had extra-articular manifestations (136). Two old reports from Zimbabwe and Nigeria described that the disease was less severe in Africa when compared to Caucasian RA patients (134, 145). We have not found any recent reports that in a strict comparative way relate the clinical presentation of RA in any African population with a Western country.

In central and western Africa the disease severity has been reported to be relatively low (133, 146, 147). Some reports from the eastern (148, 149) and southern (150, 151) parts of Africa published during the last 40 years have claimed the disease severity to be increasing.

Comparison of the diagnostic and prognostic impact of anti-CCP and RF antibodies in RA patients has been performed more extensively in industrial-ized countries compared to in Africa (144, 152). In the industrialized coun-tries the diagnostic utility of anti-CCP and RF isotypes was investigated in systematic reviews performed by Avouac et al. and Nishimura et al. These studies concluded that anti-CCP was a better marker than RF for RA diagno-sis (90, 91), as well as a better prediction marker for bone erosions (90).

Rheumatoid arthritis treatment

RA significantly affects the quality of life and can result in functional im-pairment, disability and premature death due to cardiovascular complications (153). The burden of RA affects not only individual patients and their fami-lies but also cause reduction in the total social health, utilization of health care and loss in productivity (154). The current treatment goal in RA is to achieve persistent, total disease suppression that will result in remission or cure, with improvement of the quality of life (155).

RA treatment protocols have progressed substantially over the past two decades, and treatment strategies now include not only the traditional DMARDs but also the more recently introduced biologic therapies. The most commonly prescribed DMARDs are methotrexate (MTX), anti-malarials

21

including hydroxychloroquine (HCQ), sulfasalazine (SSZ) and leflunomide. Other DMARDs include gold salts, azathioprine (AZA), cyclosporine A and cyclophosphamide. The use of DMARD combinations is more effective than monotherapy at inducing remission in patients with early RA (156).

Environmental factors and Rheumatoid arthritis

Relatively little is known about environmental factors that may contribute to the development of RA except smoking, which is the main environmental factor that has been consistently related to an increased risk of RA (157-162). Silica exposure is also an independent risk factor for RA development (163). Other factors that have been associated with development of RA in-clude lower socioeconomic status (164), dietary factors like vitamin D (165), anti-oxidants (166) and certain infections (167-170).

Several studies have reported that an increased RA risk was strongly as-sociation with the cumulative smoking exposure, denoting the importance of extent to the exposure in risk of RA development (171, 172). In addition, the interaction between genes (HLA DRB1 SE) and an environmental factor (smoking) revealed that they conferred risk to the development of RA, espe-cially in seropositive patients (i.e. RF positive and/or anti-CCP positive) (158, 173, 174). The interaction between smoking was found to occur with the HLA-DRB1*04 and HLA-DRB1*01/*10 alleles in RA patients from Sweden (161).

22

Materials and Methods

Study area, patients and establishment of VL diagnosis

The study was carried out at Tabarakalla rural hospital in Gadarif state, along the lower Atbara river in Gallabat Province, eastern Sudan. The area is located approximately about 70 kilometers southeast from Gadarif town. It is endemic for Leishmania donovani and its main vector in that area is Phlebotomus orientalis (175). Patients enrolled in the study come mainly from Tabarakalla and Barbar Elfogara villages, endemic areas with high prevalence of both VL and PKDL.

Figure 2. The outpatient clinic at Tabarakalla, Sudan.

A detailed clinical history was obtained. Particular emphasis was made

regarding any previous form of leishmaniasis. Subjects were questioned about their tribe and geographic origin, and were examined for clinical mani-

23

festations of VL. A general clinical examination was conducted with particu-lar reference to hepatosplenomegaly, enlargement of lymph nodes and pres-ence of scars as signs of previous cutaneous leishmaniasis. Liver size was measured in the mid-clavicular line from the costal margin; the spleen size was assessed by measuring the distance between the costal margins in the anterior axillary line to the tip of the spleen. Lymphadenopathy was classi-fied as localized if found only at one site and generalized if at two or more sites. The oral and nasal mucous membranes were examined for evidence of mucosal leishmaniasis. A thick and thin blood film for malaria parasites was examined from all individuals who either had fever, looked ill or had sple-nomegaly, and those with a positive blood films for malaria were excluded.

An inguinal lymph node aspiration was performed on those clinically suspected of having VL (i.e. all individuals with fever for more than 2 months, left upper quadrant pain, lymphadenopathy, splenomegaly or wast-ing). Those with a negative result underwent bone marrow aspiration from the superior posterior iliac crest. The smears were fixed with methanol, stained with Giemsa stain and examined under an oil-immersion lens using a non-electrical microscope. Severely ill VL patients from the study area were admitted to hospitals because of need for further medical care, and were classified as acute VL. Patients not severely ill and treated as outpatients with daily injections of sodium stibogluconate were classified as sub-acute VL. Patients on treatment all received daily intravenous injections of sodium stibogluconate, 20 mg/kg for 30 days, with a mean of four days between start of treatment and blood sampling. PKDL was diagnosed on clinical grounds, on the appearance and distribution of the rash after treatment in previously diagnosed VL patients. The interval between VL and the occurrence of PKDL and the duration of the rash was estimated from the patients' history.

Study area, patients and establishment of RA diagnosis

The RA project was conducted in two rheumatological outpatient units in

Khartoum (at Alribat University Hospital and Omdurman Military Hospital,

Khartoum). Blood samples and patient’s clinical records were collected be-

tween the first of December 2008 and until the end of September 2010.

The RA diagnosis were established by rheumatology specialists according to

the 1987 ACR criteria (76) and the patients were included at their first regu-

lar follow-up visit during the inclusion period. A total of 259 consecutive

Sudanese RA patients were recruited. As controls, 167 healthy blood donors

from the blood banks of Alribat University Hospital and Soba Teaching

Hospital were recruited.

24

Figure 3. The rheumatological outpatient clinic, Khartoum, Sudan.

The clinical data included age, sex, disease duration, and the number of

affected (tender and/or swollen) joints according to the EULAR 28 joint counts (176). Data on erythrocyte sedimentation rate (ESR), blood hemoglo-bin (Hb) level and X-rays of the hands including data on the occurrence of erosions and osteopenia was obtained from the patient records for 161, 169 and 84 of the patients, respectively. Information about hand and wrist de-formities (ZD, SND, BD and UD) was recorded for all patients. Age at dis-ease onset was calculated by subtracting disease duration from age at study inclusion.

Sample collection and transport to Sweden

The VL project:

Venous whole blood was drawn from the Leishmania-infected patients and their corresponding healthy controls from Tabarakalla rural hospital. The samples were drawn before treatment from newly diagnosed patients. Sera were separated by centrifugation within 2 h of collection and stored in liquid nitrogen in Tabarakalla, and thereafter stored at -70°C at Alribat University

25

Hospital in Khartoum, until transported frozen on dry ice to Uppsala, Swe-den. Samples were thawed the first time in conjunction to preparation of IC for cell culture stimulation.

The RA project:

Sudan RA patient samples and their corresponding healthy controls were collected from Alribat University Hospital and Omdurman Military Hospital. Whole blood (2.5 ml) was left to coagulate, separated by centrifugation and frozen within 2 hours of sampling. Serum samples were stored at -70°C and trans-ported frozen on dry ice to Uppsala, Sweden before analyses.

Sweden The clinical data for the Swedish RA patients were collected from the na-tional Swedish RA registry. Basic data had been interred by the patients themselves into the computerized RA registry and then completed by the responsible physician.

Polyethylene glycol precipitation of IC

Serum samples were thawed and immediately mixed with an equal volume of 5% polyethylene glycol (PEG) 6000 with 0.1M Ethylenediaminetet-raacetic acid (EDTA) and left to stand at 4°C overnight before the precipi-tates were purified and washed in a single-step centrifugation procedure described previous (177). Briefly, 1 ml of phosphate buffer saline containing 5% human serum albumin (Baxter, Kista, Sweden) and 2.5 % PEG 6000 (PBS-HSA-PEG) was added to 1.5 ml autoclaved Eppendorf tubes. Plastic cylinders made out of 5 ml autoclaved pipette tips, by cutting of about 1.5 cm of the tips, were introduced in the Eppendorf tubes containing PBS-HSA-PEG. Plasma that had been precipitated overnight were diluted 1:3 in Roswell Park Memorial Institute (RPMI)-1640 containing 2.5 % PEG 6000 and then placed on top of the PBS-HSA-PEG in the pipette tips. An interface was then formed with the less dense, red RMPI-1640 solution on top. The tubes were centrifuged at 2100g at 4°C for 20 minutes, whereby the precipi-tates in the upper 2.5% PEG-RPMI solution were centrifuged down to the bottom of the Eppendorf tubes. The remaining PBS-HSA-PEG solution was removed and the pellet containing PEG-precipitated IC was resolved in ice-cold sterile PBS of the original plasma volume. The diluted PEG precipitates were placed on ice until used in cell culture experiments.

26

Preparation of mononuclear cells and cell cultures

Buffy coats were obtained from healthy blood donors in Uppsala, and dilut-ed 1:4 in sterile PBS at room temperature, before separation on Ficoll-Paque (Amersham Pharmacia, Uppsala, Sweden). After two washes in PBS, pe-ripheral blood mononuclear cells (PBMC) were diluted to 1×106 cells/mL in RPMI-1640 supplemented with glutamine, 1% hydroxyethyl pipera-zineethanesulfonic acid (HEPES), 1% penicillin-streptomycin (PEST) and 4% Ultroser G (Flow Laboratories, Irvine, Scotland, UK). This serum free system had been optimized for studies of IC-induced cytokine responses. We have earlier found that medium supplemented with 4% Ultroser G more efficiently sustain IC induced cytokine production as compared to other se-rum substitutes (55, 177, 178). PEG-precipitates (10% v/v) were added to the cell cultures directly after PBMC preparation and within two hours of finalizing PEG precipitation. Cell cultures were performed in 300 µl vol-umes in sterile flat-bottomed 96-well plates for 20 hours before harvest of the supernatants.

Our experience of different responder cell populations used for IC stimu-lation show that PBMC populations might either be good responders to IC or show generally low or generally activated cytokine production without sub-stantial effects of added IC. Due to such variations two PBMC donors were used as responder cells in parallel in each experiment. The results presented are from the PBMC donor giving the strongest net response on IC stimula-tion, in agreement with earlier studies on IC function performed in our group (55, 178, 179).

Measurement of cytokines in supernatants

Measurement of TNFα, IL-1ß, IL-10, TNF receptor 75 (TNF-Rp75), IL-10, GM-CSF and IL-1receptor antagonist (IL-1ra) in supernatants was per-formed using enzyme-linked immunosorbent assay (ELISA). All cytokine ELISAs had been established in the laboratory for the measurement of IC-induced cytokine responses in vitro and are described elsewhere (55, 180, 181), using biotinylated detection antibodies, streptavidin-horseradish perox-idase (R&D system, Abingdon, UK), and 3,3’-5, 5’-tetramethylbenzidine (DAKO AS, Glostrup, Denmark) as substrate. The antibodies and recombi-nant cytokine standards used in the assay were purchased from R&D Sys-tems except for IL-10 (Pharmingen, San Diego, CA, USA) and TNF-Rp75 (Biosource, Nivelles, Belgium). As capture mouse monoclonal antibodies MAB610 (2.0µg/mL; for TNFα), MAB601 (2.0µg/mL; for IL-1ß), 897C2G9 (4 µg/mL; for TNF-Rp75), MAB215 (2.0µg/mL; for GM-CSF) and MAB280 (5 µg/mL, for IL-1ra) were used. For detection biotinylated polyclonal goat antibodies BAF210 (0.1µg/mL; for TNFα), BAF201

27

(2.5µg/mL; for IL-1ß), BAF280 (25 ng/mL, for IL-1ra) and mouse mono-clonal antibodies 911B3H10 (0.4 µg/mL; for TNF-Rp75) and MAB615 (2.0µg/mL; for IL-1ß) were employed. For IL-10, paired F(ab´)2 antibodies (FlexiaTM, Biosource) were used at concentrations recommended by the manufacturer. For IL-6 the capture (13A5) and the detecting antibodies (39C3) were obtained from Mabtech, Stockholm, Sweden and used at the concentrations 1 and 2 µg/mL, respectively.

FcγR blocking experiments:

Anti-FcγRII mAb (IV.3 [Fab fragment]; Medarex, Nutley, NY) or anti-FcγRIII (3G8 [Fab fragment]; Medarex) were added to the cells and left to stand at 4°C for 30 minutes before addition of dissolved PEG precipitates. The antibody concentration used was 1.5 µg/mL for both antibody frag-ments; preliminary experiments had shown equivalent blocking effect using either 1.5 or 4 μg/mL. Antibody IV.3 has earlier been shown to react specifi-cally with FcγRIIa (182).

C1q-binding assay for circulating IC

Levels of circulating IC were measured by a solid-phase C1q-binding assay (Bindazyme C1q binding kit; Binding Site, Birmingham, UK). According to the manufacturer of the kit levels above 10.8 Eq/mL are regarded as positive. The range of the assay is 1.23-100 Eq/mL.

Biochemical markers of kidney and liver functions

Plasma levels of cystatin C, creatinine, uric acid, gamma-glutamyl transfer-ase, albumin, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, and conjugated bilirubin were all measured on the Architect instrument (Abbott Laboratories, Abbott Park, IL) at the routine department of clinical chemistry, University Hospital, Uppsala, Swe-den, according to the instructions of the manufacturer.

Autoantibody measurements

RF isotypes (IgA, IgM and IgG) were measured by an enzyme immune as-say (Phadia ImmunoCAP 250, Phadia, Uppsala, Sweden). Anti-CCP was also analyzed by the same technique. Anti-CCP was considered positive when concentration was > 7 IU/ml, in accordance with the reference range

28

unitized at Uppsala University Hospital. Using this cut-off, 4/167 Sudanese healthy controls were anti-CCP positive, corresponding to a diagnostic spec-ificity of 97.6%. We then applied the same specificity level for the RF iso-types which are in accordance to the definition in the ACR criteria stating that <5% of healthy controls should be RF positive (76), a statement that has not been changed in the more recent RA classification criteria (77). Meas-urement ranges for anti-CCP was 0.4-340 arbitrary units (AU)/ml, and for IgA, IgM and IgG RF 0.4-214 international units (IU)/ml, 0.4-200 IU/ml and up to 600 µg/ml, respectively. For statistical reasons values above the refer-ence range were noted as 400 AU/ml, 250 IU/ml and 250 IU/ml for anti-CCP, IgA RF and IgM RF, respectively. All values for IgG RF were within the measurement range. For a few patients, all serum had been used up in previous investigations, and therefore some patients lack serological results.

Ethical approvals

Sudan

VL project Ethical approval for the VL project was obtained from the Ethical Commit-tee of Sudan Health Ministry in Khartoum, from the Ministry of Health at Gadarif State, and from the Ethical Committee at Uppsala University. Oral approval was also obtained from the sheikh (the alderman) in Tabarakalla village. Informed consent was obtained from all of the adults who participat-ed in the study. For young children, consent was obtained from their parents. Ethical approval for the RA project was obtained from the Ethical Commit-tee of Alribat University Hospital and Omdurman Military Hospital prior to the study, and informed consent was obtained from all patients and controls before sampling.

Sweden

The approvals for the investigations including blood sampling for PBMC preparation from healthy donors, and for the use of RA registry data for the Gävle RA patients were obtained from the regional ethical board in Uppsala.

29

Statistics:

Paper 1

T test was used for comparisons between patient groups in unpaired design, and for investigating the effects of FcγR blockade in paired design. Pear-son’s moment product correlation test was used to determine correlations, with Fisher’s R-to-S conversion to determine p values. The ratios between pro- and anti-inflammatory cytokines were determined individually for each patient or control, and the distributions of individual ratios were thereafter compared between the groups in unpaired design. Two-way analysis of vari-ance (ANOVA) was used to investigate the combined effects of disease ac-tivity and ongoing sodium stibogluconate treatment on levels of circulating IC and IC-induced cytokines.

Papers 1, 2 and 3

For the comparison of more than two groups, we used ANOVA, and for the

comparison between two groups, we used the non-parametric Mann-Whitney

test for unpaired samples. To estimate correlation between variables, we

used the Spearman non-parametric test. χ2 test was used to test for differ-

ences between proportions, using Fisher’s exact test when appropriate. Swe-

dish and Sudanese RA patients were compared both concerning the full co-

horts as well as patients with early RA (< 12 months of disease duration)

investigated separately. Receiver Operator Characteristics (ROC) curves

were constructed and area under the curve (AUC) was measured using the

Analyze-it software (Leeds, UK).

Values of p < 0.05 were considered to be significant.

30

Aims of the study

Paper 1:

To investigate the presence of circulating IC in Leishmania-infected patients and their possible role in disease pathogenesis by means of cytokine induc-tion as well as their association to disease severity and treatment.

Paper 2

To evaluate the effects of circulating IC on organ functions in patients in-fected with Leishmania donovani.

Paper 3

To investigate the appearance of RA in modern Sudan, in comparison with RA patients living in an industrialized western country (Sweden) investigat-ed during the same time period.

Paper 4

To investigate the diagnostic and prognostic properties of conventionally used RA-associated autoantibodies (anti-CCP and IgM, IgA and IgG RF isotypes) in a Sudanese RA cohort.

31

Results and Discussions

Paper 1

In this study we observed that IC precipitated from serum of Leishmania-infected patients induced significantly higher levels of GM-CSF and IL-10, as well as of IL-6 and IL-1ra as compared with PEG precipitates from matched Sudanese controls. Data showed that induction of GM-CSF by PEG-precipitated IC was especially prominent in acute VL patients undergo-ing sodium stibogluconate therapy and that IC-induced levels of GM-CSF level also paralleled serum levels of circulating IC. No other investigated cytokine showed the same parallel to IC levels.

Numerous studies have described increased levels of circulating IC con-taining parasite antigens in Leishmania infection (16, 27, 29, 30, 32-34) and that GM-CSF induced by Leishmania antigens (183) might be either benefi-cial by activating macrophages to become leishmanicidal (21, 22) or detri-mental by stimulating a Th1 response and possibly also facilitating Leishma-nia-associated kidney engagement (56, 184, 185). VL patients have shown decreasing levels of circulating IC after starting sodium stibogluconate treatment, whereas in our study the patients were sampled shortly after start of treatment. We assume that shortly after institution of antimony therapy, most likely massive numbers of parasites are being destroyed, releasing large amounts of antigen into the circulation. Then this will then result in an in-creasing load of circulating IC in the blood. This hypothesis concords with our finding of increased levels of circulating IC and IC-induced levels of GM-CSF in antimony-treated VL patients with active disease, and with the synergy between disease activity and ongoing activity as shown by two-way ANOVA. IC-induced levels of GM-CSF in vitro also correlated well with levels of circulating IC in vivo. Both measures were higher in VL patients with acute disease than in VL patients with subacute disease. The synergistic effects between circulating IC levels in vivo and GM-CSF production on response to IC in vitro on the one hand and disease activity and ongoing therapy on the other might also contribute to VL pathology. These findings indicate the importance of longitudinal studies of treated VL patients to the possible correlations between IC levels in vivo, levels of GM-CSF produced after IC stimulation in vitro, and the clinical symptoms like skin rash and signs of transient or permanent kidney involvement.

32

Paper 2

This study has shown that subjects with VL very often have impaired glo-merular filtration and that serum cystatin C levels were significantly higher when compared to PKDL patients and Sudanese healthy controls.

To test the hypothesis that circulating IC might be involved in the im-pairment of kidney functions, we correlated the circulating IC levels with levels of cystatin C. The levels of circulating IC were significantly correlated with the levels of cystatin C in subjects with VL (r=0.52, p< 0.001). A sig-nificant correlation was also seen in the subgroup of subjects with acute VL investigated separately (r=0.52, p< 0.05), whereas no such relationships were found in the subgroups with sub-acute VL or with PKDL.

In previous studies of leishmaniasis, glomerular function has been esti-mated by serum creatinine and urea levels (36-38, 40). These reports have shown varying results and have mostly been based on case studies. Creati-nine and urea levels are both confounded by several unrelated factors which seriously may hamper the detection of any reduction in glomerular filtration. It is well documented that serum creatinine levels are dependent on muscle mass, and therefore, different levels are found in adult men, women and in children. In addition, many of the subjects with VL were in poor condition, some with extensive muscle wasting, which would give rise to false-negative creatinine levels. The estimation of glomerular filtration by means of urea is even more complicated because urea, among other things, is dependent on diet and diuresis (42). With the introduction of cystatin C, an accurate and sensitive means of the estimation of GFR has become available, which is unaffected by these factors influencing creatinine and urea level (45, 186). Until now, only GFR has been shown to determine the circulating levels of cystatin C. There- fore, our findings of highly raised levels of cystatin C in the acute form of VL very clearly indicate that glomerular filtration is gener-ally impaired in this condition as opposed to among patients with sub-acute VL or PKDL.

One aim of this report was to study of the mechanisms of organ impair-ment in VL. It was therefore of considerable interest that we determined very close correlations between the amount of circulating immune complexes and GFR as estimated by cystatin C, but not as estimated by creatinine levels. IC deposition in the glomeruli thus seems to be a likely cause of renal dysfunc-tion in acute VL. Indeed, IC deposition has been previously reported in some cases with VL and also in animals infected by Leishmania (53, 54, 187-191).

In paper 1 we demonstrated elevated production of GM-CSF and some other cytokines by PBMC after incubation with serum PEG precipitates ob-tained from patients with acute VL. However, of the studied cytokines, only the production of GM-CSF was correlated with cystatin C. This was an in-teresting finding, because GM-CSF has recently been implicated in the path-ogenesis of glomerulonephritis in animal studies (184). One putative chain

33

of reactions is that circulating IC stimulate the production of GM-CSF by monocytes/macrophages and that GM-CSF enhances the production and activation of neutrophil granulocytes, which in turn react to deposited IC in the glomeruli with ensuing destruction of the tissue. Another possibility is that IC deposition in the glomeruli directly induces GM-CSF production by the mesangial cells in the glomeruli with consequent activation of neutro-phils (192).

By measuring the new and more sensitive and specific marker of glomer-ular filtration rate, cystatin C, our results re-emphasize the importance of renal dysfunction in VL and confirm earlier case reports in this matter (36-38, 40). Our study also suggests that the renal dysfunction may be directly related to the amount of circulating IC and to the induction of GM-CSF pro-duction.

We conclude that cystatin C is a superior marker of glomerular function in subjects with leishmaniasis and that IC deposition and GM-CSF are two functions which most likely are related and causally involved in the mecha-nisms leading to glomerular dysfunction in this disease. In leishmaniasis IC formation may be good for the host by the reduction of antigen deposition in certain organs, but also bad through deposition in vulnerable structures such as the glomeruli of the kidney.

Paper 3

To our knowledge this is the first ever study of the appearance of RA in Su-dan. We organized it in a comparative manner, with RA patients being in-cluded during the same time period in Sudan and Sweden. We showed that Sudanese RA patients had higher ESR and more affected joints than Swedish patients, and also rather commonly developed classical RA-associated hand and finger deformities. Sudanese RA patients were significantly younger, had a significantly lower age of disease onset, disease duration and higher female preponderance compared to Swedish RA patients. This study also showed that fewer Sudanese RA patients were IgM RF seropositive.

The general age at RA symptom onset was significantly higher among the Swedish than the Sudanese RA patients. This finding of a difference be-tween a poor and rich country concords with another recent study from Mex-ico reporting that Canadian RA patients had a higher age of onset when compared to RA patients from Mexico (193). We hypothesized that our find-ing might be secondary to the fact that Swedes have a 20 years longer life expectancy than in Sudan (194). We therefore divided our groups into five-year groups concerning age of inclusion. Contrary to our expectations we then found that for the age groups 41-45 and 46-50 years in opposite to the comparison between the full cohorts, Sudanese patients had significantly

34

higher age of disease onset. The trend was the same in all age groups above 30 years. One possible explanation for the higher age of onset among the Sudanese patients could be the higher parity among Sudanese than Swedish women (195), as high parity may lead to a delay of RA onset. Other authors showed that parity might have a protective effect on the development of RA (196-198). Another reason might be the difference in percentage IgM RF seropositivity. A Danish study reported younger RA onset age among IgM RF positive patients (199), and in our study less than half of the Sudanese patients were seropositive while the corresponding figure for Swedish pa-tients was more than 75%. However, we could not reproduce the Danish findings in our two RA populations from Sudan and Sweden investigated separately.

In our study the proportion of females in the Sudanese cohort was statisti-cally higher than among the Swedish patients. Our Swedish RA cohort with 72.5% females is representative for the full Swedish RA population that in 2008 included 58102 patients with 73% females (200). This lower female percentage in Sudan is also in agreement with corresponding figures for other countries in the Northeast of Europe: Finland (72,4%), Denmark (76,7%) and the Netherlands (66,3%) (201). On the other hand, the higher female preponderance in Sudan is in agreement with earlier African RA studies showing a high female preponderance, in Burkina Faso (81%), Egypt (85%), Cameroon (95%) and Senegal (90.6%)) (144, 152, 202, 203). Inter-nationally a high female preponderance was also described in North Ameri-can native (80%) and Malaysia (86%) (204, 205). There thus seems to be a rather uniform finding of higher percentage of female RA patients in Africa and perhaps elsewhere as compared to Europe.

RF positivity in our study was significantly lower among Sudanese than among Swedish patients, agreeing with other studies from countries in cen-tral Africa: Nigeria (13% seropositive) (147), Congo (33.3%) (137), Uganda (28%) (206), Nigeria (38.7%) (136) and Zimbabwe (37%) (207) but not with other studies from western Africa: Senegal (84% in rural areas and 88% in urban areas) (202) and Morocco (78%) (208) or eastern Africa: Kenya (77%) (209). This discrepancy may hint that in Africa different RA subsets domi-nate in different parts of the continent and that the genetic and/or environ-mental triggering mechanisms (158) might differ between different parts of Africa. No comparison for ACPA reactivity was done between the two co-horts, as the Swedish RA registry do not contain information on anti-CCP or any other ACPA. We believe the difference in the distribution of RF reac-tivity in Africa would be accompanied with the same pattern of distribution for anti-CCP reactivity, because of the close association between the occur-rence of RF and Anti-CCP both in earlier Swedish (210) and our present Sudanese cohort.

Relatively little is known about environmental factors which may con-tribute to the development of RA, except smoking, that is the main environ-

35

mental factor that has consistently been related to an increased risk of RA (157-162). Added to that, silica exposure is also an independent risk factor for RA development (163). Smoking among women is not socially accepta-ble in the Sudanese society. Earlier data on cigarette smoking in Sudan (211) show the prevalence of cigarette smoking among females to be much lower (0.7%) than among males (12.1%), data that very nicely match the occur-rence of smoking in our present RA cohort (0% and 10.7%, respectively). So what could be the triggering mechanism behind the development of RA in Sudan? We hypothesize that Sudanese dukhan (smoke baths) used by woman for their beauty could be one triggering factor for the development of RA in Sudan. Dukhan is a universal custom in Sudan were married woman used to burn a special type of woods called talh in a hole in the ground, and to sit covered by a blanket on a low footstole over this hole. Dukhan is commonly not practiced by men. The women will then be exposed to the smoke of the burning wood, the inhaled smoke may produce lung inflamma-tion leading to systemic inflammation (212). Unfortunately we have no data about dukhan habits in our cohort or in Sudan in general, but as we have a female majority (89.2%), we hypothesize that dukhan might be another environmental risk factor acting via the lungs like cigarette smoking (157-162), silica (213, 214) or traffic pollution (215) for RA development.. One argument against such a hypothesis based on pulmonary exposure is the low prevalence of autoantibody positive RA in our cohort, as the strong associa-tion shown between smoking and RA is confined to the ACPA positive RA subset, at least among Caucasians (158) and in Malaysia (216).

The disease activity in Sudanese RA patients is higher than among Swe-dish RA patients, as reflected by significantly higher ESR levels and number of affected joints among Sudanese RA patients. In comparison to what had been written about RA in Africa (135, 136, 151) our Sudanese cohort repre-sents a very active disease with high frequency of radiological erosions and many hand deformities. Report from Uganda describe that RA is severe, many of the patients (70%) with erosions and less than 30% of the patients with IgM RF (206) . From our results and the Ugandan data there seem to be a clustering of highly active seronegative RA in central Africa.

The modalities of treatment used were similar in the two populations ex-cept for biologics that were used only in Sweden. Most probably this is a cost issue, as Sudanese patients besides having tighter budget than Swedish patients also pay their own drugs, whereas Swedish patients are part of a social system where society pays all prescribed drugs over a certain limit (currently approximate to 250 Euro/year). Yet there has also been an argu-ment that TNF blockers might impose safety issues in developing countries where the proportion of inhabitants with manifest of latent tuberculosis is high (141, 217). Although proportions of patients treated with NSAID only were small in both populations, significantly more Sudanese patients had

36

such treatment regiment. Reasons might be both due to costs and to patients’ unwillingness to be treated with ‘cytotoxic drugs’.

Perhaps the most interesting finding concerning treatment differences was the difference in use of MTX, DMARD combinations and prednisolone. Generally Sudanese patients used lower doses of MTX and higher doses of prednisolone than Swedish patients. And especially among patients with short disease duration, the Sudanese patients were significantly less often treated with MTX or with DMARD combinations. Reasons might be fear of using cytotoxic agents and level of education. The somewhat higher doses of prednisolone in Khartoum might also be due to a wish to obtain a fast clini-cal response in patients with flares, in a health care context where intensive follow-up is difficult. The study is only cross-sectional concerning the Suda-nese patients, however, and we have no longitudinal data on drug use. The time given for introduction of a newly diagnosed RA patient differs consid-erably between the two settings. Whereas a Swedish patient might attend a one-hour visit with the rheumatologist to get introduction to her/his disease and its treatment, the corresponding time in Khartoum is considerably less, mostly around 25 minutes.

We have found that Sudanese RA patients have strikingly more wide-spread joint involvement and stronger laboratory signs of inflammation as compared to Swedish RA patients during the same inclusion period. Suda-nese patients also to a large extent have radiological erosions and RA-associated hand deformities, although only less than half of the patients are IgM RF seropositive. This finding of highly active seronegative RA in cen-tral Africa contrasts to the rather widespread belief that RA in Africa has a mild clinical course. The fact that Sudanese RA patients use lower metho-trexate doses and higher prednisolone doses, and that fewer early RA pa-tients use DMARD combinations or MTX monotherapy might be due to structural dissimilarities between health care systems, economic prerequi-sites, and different possibilities for clinical follow-up of RA patients in Su-dan and Sweden.

Paper 4

According to our knowledge, this study is the first report that describes the diagnostic and prognostic properties of conventionally used RA-associated autoantibodies (anti-CCP and RF of the IgM, IgG and IgA isotypes) in a Sudanese RA cohort.

In our study we found that IgA RF was the most common autoantibody (56%) followed by anti-CCP and IgM RF (both 52%) and then by IgG RF (49.8%). The occurrence of anti-CCP was rather similar to what has been found among Swedish RA patients (56%) (210). The relative order of IgA and IgM RF isotypes are in agreement with a Cameroon study by Singwe-

37

Ngandeu et al, which reported a higher prevalence of IgA RF (84%) fol-lowed by IgM RF (77%); IgG RF was not investigated in that study (144). The frequency different RF isotypes does however differ from the IgM RF predominance that is commonly described in Caucasian RA patients. A study from Germany by Vallbracht et al. showed that IgM RF (66.4%) was the predominant type, closely followed by anti-CCP (64.4%), with lower frequencies of IgA RF (50.8%) and IgG RF (43.7%) (85). Another study from Sweden reported the same frequency order for RF isotypes, were IgM RF was found in (79%) of the RA cases, followed by IgA (78%) and IgG RF (68%) (84). Asian RA studies on the other hand report the lowest fre-quency for IgA RF. A study from India by Singh et al. showed a relative increase in impact for IgG RF, with 48% IgM RF positive RA patients, fol-lowed by IgG RF (42%) and IgA RF (37%)(218). A study in three ethnic groups (Malay, Chinese and Indian) living in Malaysia (219) also showed the same pattern of distribution for RF isotypes as in India (218). IgM RF (53.1%) was the most common autoantibody among these Malaysian pa-tients followed by IgG RF (48.3%) and then by IgA RF (21.1%).

Thus there seem to a be a relative difference in RF isotype distribution be-tween RA patients from three continents, with IgA RF predominating in Africa [(144) and this study], IgM RF predominating in Europe (84, 85) and with a relative increase in IgG RF and decrease in IgA RF in Asia (218, 219). A report on the predominance of IgM RF (70%) over IgA RF (65%) among African American RA patients (220) show data corresponding to the isotype distribution among native American RA patient from the same con-tinent (221) but differing from black patient in Africa as shown by Singwe-Ngandeu et al (144) and by us. This study of African American RA patients thus argues for divergent environmental triggers for RF isotype distribution in different continents. The fact that the same pattern is seen in three ethni-cally distinct populations in Malaysia (219) indicates that this difference primarily is driven by environmental and not by genetic factors. Another fact also indicating that there might be environmental factors generally facilitat-ing the production of IgA autoantibodies in Africa is the high prevalence of IgA anti-cardiolipin antibodies in African patients with SLE (222, 223), alt-hough IgA anti-phospholipid antibodies are no part of the presently used anti-phospholipid syndrome criteria (224).

When RF status is compared in different studies, a weakness is the lack of precision in the definition of RF cut-offs in the 1987 ACR classification criteria (76) and which have not been changed in the current 2010 ACR/EULAR classification criteria (77). The 1987 ACR criteria state that any technique can be used for RF determination, but that the diagnostic spec-ificity should be >95% compared to healthy controls. There is however no definition of upper specificity limits, implying that e.g. a cut-off of 400 IU/ml for IgM RF is compatible with the RA criteria, although only a minor-ity of RA patients normally regarded as IgM RF seropositive have such RF

38

levels. Today ACPA analyses are performed without any international standardization at all. A first international ACPA reference preparation was recently described, showing a >5 times difference in cut-off relative to the standard preparation (225). In our study we have very carefully aligned the specificity to be the same for all investigated antibodies, using national Su-danese healthy controls to define this diagnostic specificity, and to our knowledge this approach is seldom or never used, and we have not found any such studies from the African continent. Our finding could reflect that the diagnostic utility of IgA RF isotype may be more important than IgM RF and anti-CCP tests in African patients with RA.

For further comparisons of the diagnostic value of each assay, we under-took an ROC curve analysis and calculated the AUC. The ROC analysis displays pairs of sensitivity and specificity for different cut-off points of anti-CCP, IgG RF, IgA RF, and IgM RF concentrations. The AUC was highest for IgA RF. This fact also strengthens our perception that IgA RF is the best marker for detecting RA patients in central Africa, and that serologi-cal screening for RA might be performed primarily with IgA RF. Another recent RA report from central Africa (Congo) showed that the occurrence of IgM RF in their patients was infrequent (33%) (137). It would thus be inter-esting to see whether Congolese RA patients also have an IgA RF predomi-nance as determined by us and in Cameroon (144). Use of the diagnostically most sensitive serological screening test will aid in early identification of more Sudanese RA patients, and early start of DMARD treatment to prevent joint destruction and disability as has been internationally recommended (226).

But even if IgA RF is superior to anti-CCP when the cut-off is set accord-ing to healthy controls, what really matters in real life health care is how the antibodies perform compared to disease controls. The clinical breakthrough for anti-CCP came when this antibody proved to have superior specificity compared to RF when patients with other rheumatic conditions and infec-tions, i.e. relevant disease controls, were investigated (92). To really prove our hypothesis that IgA RF is the superior diagnostic marker, all antibodies should be investigated among relevant Sudanese disease controls; patients with other systemic inflammatory diseases or chronic infections.

When comparing the prognostic impact for all investigated autoantibod-ies, IgG RF isotype was shown to be the strongest marker for bad prognosis due to its association with younger age at inclusion, lower age of disease onset and hand deformities in our cohort. The striking finding in our study is that anti-CCP did not have the biggest prognostic impact on the clinical out-come for our patients, in contrast to what is commonly described (227, 228). Early studies have shown association between bone destruction and RF iso-types (229-231), and neither could we repeat this finding. Even if such an association between autoantibodies and radiological destruction would exist in Sudan, there are a number of reasons why we might lack this association:

39

few patient with X-ray data (32%), a cross-sectional design with different disease duration at the time of imaging and reporting only of qualitative X-ray data investigated by from different radiologists.

Intriguingly, when we assessed the correlation between anti-CCP and the different RF isotypes in our RA cohort, IgG RF correlated only weakly to anti-CCP levels, but more strongly with the other RF isotypes, indicating that any clinical associations to IgG RF in our cohort are not secondarily dependent on the simultaneous occurrence of anti-CCP. Our findings imply that the IgG RF isotype is the strongest marker of bad prognosis for Suda-nese RA patients.

To conclude: the percentage of autoantibody-positive RA patients in Su-dan is quite low, and IgA seem to be the most diagnostically sensitive mark-er, although crucial comparisons with national disease controls currently are lacking. IgG RF seem to be the strongest prognostic marker associated with young age of disease onset and with the occurrence of hand deformities. This is the first study for the role of autoantibodies in Sudanese RA patients, and will be followed by further studies.

40

Future perspective

Visceral Leishmaniasis in Sudan

In the literature there is a markedly divergent propensity to PKDL develop-ment between VL patients from Sudan and India (15). The tendency to de-velop PKDL probably depends on the single individuals’ unique response to sodium stibogluconate treatment, parasite load, genetic predisposition, envi-ronmentally acquired traits, or a combination of such factors. In our future we would like to pursue the following lines of investigation:

1. To investigate what factors could determine the development of PKDL. Gasim et al showed that plasma levels of IL-10 and keratinocyte expression of IL-10 in VL patients may predict PKDL development and that patients who later developed PKDL also had significantly larger spleens (16). This might reflect a heavier load of parasites or circulating IC containing parasite antigens sequestered in the spleen. In theory, strong IL-10 responses and as in our study GM-CSF responses in PKDL patients might reflect a larger parasite load.

2. To investigate the presence of genetic alterations (polymorphisms) that can exist in inflammatory cells such as eosinophils, neutrophils and monocytes and their association to the development of Leishma-nia donovani infection and especially VL. Especially I want to in-vestigate polymorphism in proteins associated with eosinophil and neutrophil granulocytes: eosinophilic cationic protein, myeloperoxi-dase and eosinophil protein X.

3. Skin biopsy examinations for the presence of IC deposition and cy-tokine expression in diseased and non-diseased areas in patients with PKDL. The biopsies will be analyzed for parasite antigens, cellular markers for eosinophilic cationic protein and myeloperoxidase and infiltrating cells.

Rheumatic diseases in Sudan

Our autoimmunity group has a good knowledge and experiences in the field of rheumatic diseases with special focuses on patients with RA and systemic

41

lupus erythematous (SLE) (210, 232-234). We established our current RA project since 2008 and in 2011 we started a new project were we targeted patients with SLE from three rheumatological units in Sudan. Sample collec-tion in the SLE project will be ended in August 2013.

Rheumatoid arthritis

In future we are aiming to do the following sub-projects in RA patients: 1- To look for the association between autoantibodies, HLA and smok-

ing in our cohort, compared with Swedish and Malaysian cohorts (158, 235).

2- The Sudanese RA cohort will be compared to Swedish RA patients concerning: i) Anti-CCP isotypes (IgG, IgA and IgM), using the same tech-

niques described by our group (236, 237). ii) Anti-type II collagen antibodies, using the same techniques de-

scribed by our group (238-240). iii) Anti-phospholipid antibodies (IgG/A/M anti-cardiolipin and an-

ti-beta2GP1). 3- We need to investigate our cohort for the presence of RA-associated

point mutations in the HLA region, PTPN22 and for other RA-associated susceptibility loci (241).

4- We will use the Phadia's ImmunoCAP ISAC microarray system for identification of a multiple RA-associated autoantibodies against the candidate autoantigens citrullinated fibrinogen, α-enolase, vimentin and collagen type II. We will compare our findings with the Swedish Epidemiological Investigation of Rheumatoid Arthritis case control data as recently described by others (242) as well as with the Malay-sian RA cohort (Too Chun Lai, Rönnelid et al, to be published), to get an understanding on whether the same fine specificity of the an-ti-citrulline response is found in different parts of the world.

Systemic lupus erythematous

Nothing has so far been published internationally about the clinical picture of SLE in Sudan and our current ongoing SLE project will represent the first one. When we will finish our sample collection (August, 2013) we are aim-ing to compare it with a cohort from Karolinska Hospital in collaboration with Iva Gunnarsson and Elisabet Svenungsson.

42

Acknowledgments

This work was carried out at the Department of Immunology, Genetics and Pathology, Faculty of Medicine, Uppsala University. This investigation was supported by grants from the Swedish Research Council, the Swedish Rheumatism Association, the King Gustav V 80-year foundation, the Agnes and Mac Rudberg Foundation, the InDevelop Foundation, ALF grants from Uppsala University Hospital, the Signe and Reinhold Sund Foundation for Rheumatological Research, the Capio Research Foundation and the Clas Groschinsky Foundation. I would like to express my warmest gratitude to all those who have help me in various ways and contributed to finish my thesis. I would like to especial-ly thank: My supervisor Johan Rönnelid, my best friend and my good supervisor who introduced me to the different fields in clinical immunology from basic immunology to cellular immunodiagnostic and research. For always having an open door and warm heart to share your knowledge and discuss science as well as life. For your critical reading, endless support and your nice attitude that allowed me to promote my self in the depth of the science.

My co-supervisor in Sweden Per Venge (the father of science), for your unlimited care and support and your constructive suggestions during our meetings which have been of such great benefit for improving my work and writing my manuscripts.

My co-supervisor in Sudan Sayda Hassan Elsafi, for all the help that you provided in Sudan.

My colleagues Linda Mathsson, Mohammed Mullazehi and Erik Åhlin, who introduced me to the fields of immune complexes and cytokine meas-urement. And also to my current colleagues Azita Sohrabian, Vivek Anand and Belinda Norin for being so supportive and valuable in my research. Special thanks to Osama Hamad, Jennie Bäck and Huda Kozarcanin. Robert Harris for linguistic advice.

43

All other co-authors from Sudan (Musa Nur, Elnour Elagib, Mawahib Aledrissy, Sahwa Nourein and Nasr-Eldeen Gaufri), Gävle Hospital (Abdalla ElKhalifa and Thomas Weitoft)

and Uppsala University Hospital

(Lena Håkansson, Ulla-Britt Jönsson, Jenny Rubin and Kristin Blom) for their nice collaborations and unlimited support.

Abdal-Latif Ashmaig, Hashim Erwa, and A. G. Eltahir, Anwar Al-kordofani, Maria Satti, Abdelrahman Tambal and Ismael Abdelrahman and all colleagues in the field of clinical pathology and rheumatology in Sudan for their great support and inspiration. Special thank to all patients and doctors at Tabarakalla and Khartoum hospitals. The personnel at the routine lab in the unit of clinical immunology at Uppsa-la University Hospital for letting me use all necessary equipment.

The administrative staff at the department of immunology, genetics and pa-thology, for all the help with practical issues.

My Sudanese colleagues from all Swedish universities and our diplomatic staff at Sudan embassy, Sweden.

To all members in the Sudanese societies in Uppsala and Stockholm.

To my deepest debt of gratitude family; Isam, Yasir, Shehab, Ammar, Tamador, Elshafie, Marwa, Samaha, Nadia, Anfal, Tamir, Reela, Tala, Hassan, Abbassa, Mayassa and many Others, for their unlimited support, patience, understanding and encouragement throughout the years of my stud-ies.

The most special thanks I accord to my mum, Asha, for her unwavering understanding and support, selfless love, her encouragement and her Doa through my life especially during the preparation of this thesis.

Finally, this thesis is dedicated to my father’s soul, who encouraged me all the way long. I wish he could be here to see his dream come true.

44

References

1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996;14(5):417-23.

2. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154(6):1003-11.

3. Badaro R, Jones TC, Lorenco R, Cerf BJ, Sampaio D, Carvalho EM, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis. 1986;154(4):639-49.

4. Southgate BA, Manson-Bahr PE. Studies in the epidemiology of East African leishmaniasis. 4. The significance of the positive leishmanin test. J Trop Med Hyg. 1967;70(2):29-33.

5. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg. 1994;51(6):826-36.

6. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2001;95 Suppl 1:S27-58.

7. Elnaiem DE. Ecology and control of the sand fly vectors of Leishmania donovani in East Africa, with special emphasis on Phlebotomus orientalis. J Vector Ecol. 2011;36 Suppl 1:S23-31.

8. Rosenzweig D, Smith D, Myler PJ, Olafson RW, Zilberstein D. Post-translational modification of cellular proteins during Leishmania donovani differentiation. Proteomics. 2008;8(9):1843-50.

9. Alexander J, Russell DG. The interaction of Leishmania species with macrophages. Adv Parasitol. 1992;31:175-254.

10. Sacks DL. Metacyclogenesis in Leishmania promastigotes. Exp Parasitol. 1989;69(1):100-3.

11. Zilberstein D, Shapira M. The role of pH and temperature in the development of Leishmania parasites. Annu Rev Microbiol. 1994;48:449-70.

12. Boelaert M, Meheus F, Robays J, Lutumba P. Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol. 2010;104(7):535-42.

13. Khalil EA, Musa AM, Elgawi SH, Meshasha A, Gamar Eldawla I, Elhassan MO, et al. Revival of a focus of visceral leishmaniasis in central Sudan. Ann Trop Med Parasitol. 2008;102(1):79-80.

14. Pearson RD, Sousa AQ. Clinical spectrum of Leishmaniasis. Clin Infect Dis. 1996;22(1):1-13.

15. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87-98.

16. Gasim S, Elhassan AM, Khalil EA, Ismail A, Kadaru AM, Kharazmi A, et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during

45

visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol. 1998;111(1):64-9.

17. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol. 2003;24(3):148-54.

18. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol. 1990;144(12):4794-7.

19. Sang DK, Ouma JH, John CC, Whalen CC, King CL, Mahmoud AA, et al. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J Infect Dis. 1999;179(3):743-6.

20. Jones TC. The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med Oncol. 1996;13(3):141-7.

21. Al-Zamel F, Al-Shammary FJ, El-Shewemi S, Soliman R. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralbl Bakteriol. 1996;285(1):92-105.

22. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest. 1995;95(3):1183-92.

23. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis. 1994;170(2):413-8.

24. Cotterell SE, Engwerda CR, Kaye PM. Leishmania donovani infection of bone marrow stromal macrophages selectively enhances myelopoiesis, by a mechanism involving GM-CSF and TNF-alpha. Blood. 2000;95(5):1642-51.

25. Dumas C, Muyombwe A, Roy G, Matte C, Ouellette M, Olivier M, et al. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun. 2003;71(11):6499-509.

26. Singal P, Singh PP. Leishmania donovani amastigote component-induced colony-stimulating factor production by macrophages: modulation by morphine. Microbes Infect. 2005;7(2):148-56.

27. Pearson RD, de Alencar JE, Romito R, Naidu TG, Young AC, Davis JSt. Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J Infect Dis. 1983;147(6):1102.

28. Kharazmi A, Rezai HR, Fani M, Behforouz NC. Evidence for the presence of circulating immune complexes in serum and C3b and C3d on red cells of kala-azar patients. Trans R Soc Trop Med Hyg. 1982;76(6):793-6.

29. Kager PA, Hack CE, Hannema AJ, Rees PH, von dem Borne AE. High C1q levels, low C1s/C1q ratios, and high levels of circulating immune complexes in kala-azar. Clin Immunol Immunopathol. 1982;23(1):86-93.

30. Sehgal S, Aikat BK, Pathania AG. Immune complexes in Indian kala-azar. Bull World Health Organ. 1982;60(6):945-50.

31. Galvao-Castro B, Sa Ferreira JA, Marzochi KF, Marzochi MC, Coutinho SG, Lambert PH. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol. 1984;56(1):58-66.

46

32. Makni S, Ayed K, Ben Said M, Ben Rachid MS. Study of circulating immune complexes during the evolution of visceral Mediterranean leishmaniasis. Ann Trop Med Parasitol. 1989;83(4):349-55.

33. Mary C, Ange G, Dunan S, Lamouroux D, Quilici M. Characterization of a circulating antigen involved in immune complexes in visceral leishmaniasis patients. Am J Trop Med Hyg. 1993;49(4):492-501.

34. Chakraborti T, Sarkar D, Ghosh DK. Immune complex antigens as a tool in serodiagnosis of kala-azar. Mol Cell Biochem. 2003;253(1-2):191-8.

35. Abreu-Silva AL, Calabrese KS, Cupolilo SM, Cardoso FO, Souza CS, Goncalves da Costa SC. Histopathological studies of visceralized Leishmania (Leishmania) amazonensis in mice experimentally infected. Vet Parasitol. 2004;121(3-4):179-87.

36. Caravaca F, Munoz A, Pizarro JL, Saez de Santamaria J, Fernandez-Alonso J. Acute renal failure in visceral leishmaniasis. Am J Nephrol. 1991;11(4):350-2.

37. Marcussen N, Vetner M, Kristensen HM. Interstitial nephritis and glomerulonephritis in visceral leishmaniasis in a dog. A case report. APMIS. 1989;97(12):1137-40.

38. DE Brito T, S. H-S, Neto V, Duarte I, Penna D. Glomerular involvement in human kala-azar. A light, immunofluorescent, and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg. 1975;24(1):9-18.

39. Tafuri WL, de Oliveira MR, Melo MN, Tafuri WL. Canine visceral leishmaniosis: a remarkable histopathological picture of one case reported from Brazil. Vet Parasitol. 2001;96(3):203-12.

40. Weisinger JR, Pinto A, Velazquez GA, Bronstein I, Dessene JJ, Duque JF, et al. Clinical and histological kidney involvement in human kala-azar. Am J Trop Med Hyg. 1978;27(2 Pt 1):357-9.

41. Seronie-Vivien S, Delanaye P, Pieroni L, Mariat C, Froissart M, Cristol JP. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46(12):1664-86.

42. Bishop M, Duben-Engelkirk J, Fody E. Clinical Chemistry; Principles, Procedures, Correlations. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.

43. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H. Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest. 1998;58(7):585-92.

44. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest. 1985;45(2):97-101.

45. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38 Suppl 1:S20-7.

46. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36(1):29-34.

47. Westhuyzen J. Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci. 2006;36(4):387-94.

48. Suzuki Y, Matsushita K, Seimiya M, Yoshida T, Sawabe Y, Ogawa M, et al. Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes. Clin Chem Lab Med. 2012;50(10):1833-9.

49. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61(4):1453-61.

47

50. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47(1):312-8.

51. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115-22.

52. Fouad M, Boraie M. Cystatin C as an early marker of acute kidney injury and predictor of mortality in the intensive care unit after acute myocardial infarction. Arab J Nephrol Transplant. 2013;6(1):21-6.

53. Jain A, Berthwal M, Tiwari V, Maitra SC. Immune complex mediated lesions in experimental Kala azar: an ultrastructural study. Indian J Pathol Microbiol. 2000;43(1):13-6.

54. Sartori A, De Oliveira AV, Roque-Barreira MC, Rossi MA, Campos-Neto A. Immune complex glomerulonephritis in experimental kala-azar. Parasite Immunol. 1987;9(1):93-103.

55. Mathsson L, Tejde A, Carlson K, Höglund M, Nilsson B, Nilsson-Ekdahl K, et al. Cryoglobulin-induced cytokine production via FcgammaRIIa: inverse effects of complement blockade on the production of TNF-alpha and IL-10. Implications for the growth of malignant B-cell clones. Br J Haematol. 2005;129(6):830-8.

56. Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR. Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med. 1996;2(3):297-312.

57. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681-90.

58. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105-10.

59. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, Jr., et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002;8(3):231-40.

60. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.

61. Pablos JL, Canete JD. Immunopathology of rheumatoid arthritis. Curr Top Med Chem. 2013;13(6):705-11.

62. Firestein GS, Zvaifler NJ. The pathogenesis of rheumatoid arthritis. A critical assessment of the role of autologous stimulation in the perpetuation of rheumatoid synovitis. Rheum Dis Clin North Am. 1987;13(3):447-61.

63. Fox DA. Rheumatoid Arthritis--heresies and speculations. Perspect Biol Med. 1997;40(4):479-91.

64. Zhang Z, Bridges SL, Jr. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am. 2001;27(2):335-53.

65. Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci. 2002;323(4):171-80.

66. Cascao R, Moura RA, Perpetuo I, Canhao H, Vieira-Sousa E, Mourao AF, et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R196.

48

67. Moura RA, Graca L, Fonseca JE. To B or not to B the conductor of rheumatoid arthritis orchestra. Clin Rev Allergy Immunol. 2012;43(3):281-91.

68. Konisti S, Kiriakidis S, Paleolog EM. Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(3):153-62.

69. Moura RA, Weinmann P, Pereira PA, Caetano-Lopes J, Canhao H, Sousa E, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford). 2010;49(6):1082-92.

70. Moura RA, Cascao R, Perpetuo I, Canhao H, Vieira-Sousa E, Mourao AF, et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford). 2011;50(2):278-82.

71. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005;72(6):1037-47.

72. Karlson EW, Deane K. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am. 2012;38(2):405-26.

73. Klareskog L, Lundberg K, Malmström V. Autoimmunity in rheumatoid arthritis: citrulline immunity and beyond. Adv Immunol. 2013;118:129-58.

74. Ainola M. Pannus invation into cartilage and bone in Rheumatoid arthritis. Finland: Helsinki University Central Hospital; 2009.

75. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis--I: Clinical features and diagnosis. BMJ. 1995;310(6979):587-90.

76. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.

77. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.

78. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford). 2002;41(7):809-14.

79. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, vanVenrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta. 2004;350(1-2):17-34.

80. Waaler E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. APMIS. 2007;115(5):422-38; discussion 39.

81. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol. 1998;37(2):126-30.

82. Wernick RM, Lipsky PE, Marban-Arcos E, Maliakkal JJ, Edelbaum D, Ziff M. IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum. 1985;28(7):742-52.

83. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731-6.

84. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196-201.

49

85. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004;63(9):1079-84.

86. Borretzen M, Chapman C, Natvig JB, Thompson KM. Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ-line gene usage. Eur J Immunol. 1997;27(3):735-41.

87. Thompson KM, Randen I, Borretzen M, Forre O, Natvig JB. Variable region gene usage of human monoclonal rheumatoid factors derived from healthy donors following immunization. Eur J Immunol. 1994;24(8):1771-8.

88. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273-81.

89. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162(1):585-94.

90. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.

91. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845-51.

92. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155-63.

93. Trouw LA, Huizinga TW, Toes RE. Autoimmunity in rheumatoid arthritis: different antigens--common principles. Ann Rheum Dis. 2013;72 Suppl 2:ii132-6.

94. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003;25(11):1106-18.

95. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 2001;44(1):41-7.

96. Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010;103(3):139-46.

97. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177-84.

98. van Oosterhout M, Bajema I, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum. 2008;58(1):53-60.

50

99. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67(2):212-7.

100. van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2232-41.

101. Weinblatt ME, Schur PH. Rheumatoid factor detection by nephelometry. Arthritis Rheum. 1980;23(6):777-9.

102. Saraux A, Berthelot JM, Chales G, Le Henaff C, Mary JY, Thorel JB, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum. 2002;47(2):155-65.

103. Bas S, Perneger TV, Kunzle E, Vischer TL. Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis. 2002;61(6):505-10.

104. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001;47(6):1089-93.

105. Kamoun M. Diagnostic performance and predictive value of anti-citrullinated peptide antibodies for diagnosis of rheumatoid arthritis: toward more accurate detection? Clin Chem. 2005;51(1):12-3.

106. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol. 2003;32(4):197-204.

107. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000;43(8):1831-5.

108. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004;50(3):709-15.

109. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol. 2005;32(2):231-8.

110. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford). 2003;42(5):677-80.

111. Jonsson T, Steinsson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Rheumatol Int. 1998;18(3):119-22.

112. Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7(7):e40362.

113. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146-54.

51

114. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999;97(2):188-96.

115. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum. 2000;43(3):608-16.

116. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66(3):302-7.

117. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81.

118. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-400.

119. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003;48(1):46-53.

120. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-9.

121. Teitsson I, Valdimarsson H. Use of monoclonal antibodies and F(ab')2 enzyme conjugates in ELISA for IgM, IgA and IgG rheumatoid factors. J Immunol Methods. 1984;71(2):149-61.

122. Can M, Najip A, Yilmaz N, Inanc N, Yavuz S. Immunoglobulin subtypes predict therapy response to the biologics in patients with rheumatoid arthritis. Rheumatol Int. 2013;33(6):1455-60.

123. Zlabinger GJ, Haberhauer G, Dax K, Menzel EJ, Broll H. Rheumatoid factor isotypes and circulating immune complexes in rheumatoid arthritis. Clin Exp Rheumatol. 1990;8(2):113-9.

124. Jorgensen C, Legouffe MC, Bologna C, Brochier J, Sany J. IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp Rheumatol. 1996;14(3):301-4.

125. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65(4):453-8.

126. Pope RM, McDuffy SJ. IgG rheumatoid factor. Relationship to seropositive rheumatoid arthritis and absence in seronegative disorders. Arthritis Rheum. 1979;22(9):988-98.

127. Silvestris F, Goodwin JS, Williams RC, Jr. IgM, IgA and IgG rheumatoid factors in patients with rheumatoid arthritis and normal donors. Clin Rheumatol. 1985;4(4):392-8.

128. Hay FC, Nineham LJ, Roitt IM. Routine assay for detection of IgG and IgM antiglobulins in seronegative and seropositive rheumatoid arthritis. Br Med J. 1975;3(5977):203-4.

52

129. Jonsson T, Arinbjarnarson S, Thorsteinsson J, Steinsson K, Geirsson AJ, Jonsson H, et al. Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 1995;24(6):372-5.

130. Sihvonen S, Korpela M, Mustila A, Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32(11):2089-94.

131. Kelgren J H JMR, Ball J. . The epidemiology of chronic rheumatism. . Oxford: Blackwell 1963: 324-7 (Proceedings of symposium, Rome). 1963.

132. Muller AS, Valkenburg HA, Greenwood BM. Rheumatoid arthritis in three west African populations. East Afr Med J. 1972;49(2):75-83.

133. McGill P. Rheumatoid arthritis in sub-Saharan Africa. Ann Rheum Dis. 1991;50(12):965-6.

134. Adebajo AO, Reid DM. The pattern of rheumatoid arthritis in West Africa and comparison with a cohort of British patients. Q J Med. 1991;80(292):633-40.

135. Beighton P, Solomon L, Valkenburg HA. Rheumatoid arthritis in a rural South African Negro population. Ann Rheum Dis. 1975;34(2):136-41.

136. Adelowo OO, Ojo O, Oduenyi I, Okwara CC. Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic. Clin Rheumatol. 2010;29(6):593-7.

137. Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Bossuyt X, Verschueren P, Westhovens R. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo--a population-based study. Rheumatology (Oxford). 2012;51(9):1644-7.

138. McGill PE, Oyoo GO. Rheumatic disorders in Sub-saharan Africa. East Afr Med J. 2002;79(4):214-6.

139. Mody GM. Rheumatoid arthritis and connective tissue disorders: sub-Saharan Africa. Baillieres Clin Rheumatol. 1995;9(1):31-44.

140. Mody GM, Meyers OL. Rheumatoid arthritis in blacks in South Africa. Ann Rheum Dis. 1989;48(1):69-72.

141. Kalla AA, Tikly M. Rheumatoid arthritis in the developing world. Best Pract Res Clin Rheumatol. 2003;17(5):863-75.

142. Kilgore L. Possible case of rheumatoid arthritis from Sudanese Nubia. Am J Phys Anthropol. 1989;79(2):177-83.

143. Brighton SW, de la Harpe AL, van Staden DJ, Badenhorst JH, Myers OL. The prevalence of rheumatoid arthritis in a rural African population. J Rheumatol. 1988;15(3):405-8.

144. Singwe-Ngandeu M, Finckh A, Bas S, Tiercy JM, Gabay C. Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients. Arthritis Res Ther. 2010;12(2):R36.

145. Chikanza IC, Stein M, Lutalo S, Gibson T. The clinical, serologic and radiologic features of rheumatoid arthritis in ethnic black Zimbabwean and British Caucasian patients. J Rheumatol. 1994;21(11):2011-5.

146. Adebajo AO. Rheumatoid arthritis: a twentieth century disease in Africa? Arthritis Rheum. 1991;34(2):248-9.

147. Greenwood BM. Polyarthritis in Western Nigeria. I. Rheumatoid arthritis. Ann Rheum Dis. 1969;28(5):488-96.

148. Bagg LR, Hansen DP, Lewis C, Houba V. Rheumatoid arthritis in Kenya. I. Clinical observations. Ann Rheum Dis. 1979;38(1):23-5.

53

149. Kanyerezi BR, Lutalo SK. Some aspects of rheumatoid disease in Uganda. East Afr Med J. 1980;57(1):39-43.

150. Moolenburgh JD, Moore S, Valkenburg HA, Erasmus MG. Rheumatoid arthritis in Lesotho. Ann Rheum Dis. 1984;43(1):40-3.

151. Solomon L, Robin G, Valkenburg HA. Rheumatoid arthritis in an urban South African Negro population. Ann Rheum Dis. 1975;34(2):128-35.

152. Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol. 2008;37(5):329-36.

153. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8-14.

154. Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol. 2011;30 Suppl 1:S3-8.

155. Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol. 2010;37(8):1570-8.

156. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.

157. Klareskog L, Padyukov L, Rönnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol. 2006;18(6):650-5.

158. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46.

159. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum. 2007;56(6):1745-53.

160. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis. 2006;65(3):366-71.

161. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 2009;60(6):1597-603.

162. Mikuls TR, Sayles H, Yu F, Levan T, Gould KA, Thiele GM, et al. Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis Rheum. 2010;62(12):3560-8.

163. Stolt P, Yahya A, Bengtsson C, Källberg H, Rönnelid J, Lundberg I, et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1072-6.

164. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(3):279-83.

165. Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis. 2008;67(4):530-5.

54

166. Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell LA. Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol. 2003;157(4):345-54.

167. Mangat P, Wegner N, Venables PJ, Potempa J. Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther. 2010;12(3):209.

168. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662-72.

169. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol. 2010;6(12):727-30.

170. Dissick A, Redman RS, Jones M, Rangan BV, Reimold A, Griffiths GR, et al. Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol. 2010;81(2):223-30.

171. Karlson EW, Chang SC, Cui J, Chibnik LB, Fraser PA, De Vivo I, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):54-60.

172. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med. 2006;119(6):503 e1-9.

173. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50(10):3085-92.

174. Källberg H, Padyukov L, Plenge RM, Rönnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80(5):867-75.

175. Hoogstraal H, Heyneman D, Dietlein DR, Browne HG, PF RTJVP, Saber AH, et al. Leishmaniasis in the Sudan Republic: epidemiological findings. Bull World Health Organ. 1963;28(2):263-5.

176. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.

177. Pontes-de-Carvalho LC, Lannes-Vieira J, Giovanni-de-Simone S, Galvao-Castro B. A protein A-binding, polyethylene glycol precipitation-based immunoradiometric assay. Application to the detection of immune complexes and C3 in human sera and of private antigens in cross-reacting parasite extracts. J Immunol Methods. 1986;89(1):27-35.

178. Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther. 2006;8(3):R64.

179. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum. 2006;54(6):1759-71.

55

180. Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62(1):37-42.

181. Tejde A, Mathsson L, Ekdahl KN, Nilsson B, Rönnelid J. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system. Clin Exp Immunol. 2004;137(3):521-8.

182. Vely F, Gruel N, Moncuit J, Cochet O, Rouard H, Dare S, et al. A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma. 1997;16(6):519-28.

183. Singal P, Singh PP. Leishmania donovani amastigote components-induced colony-stimulating factors production. Parasitol Int. 2005;54(1):9-20.

184. Kitching AR, Ru Huang X, Turner AL, Tipping PG, Dunn AR, Holdsworth SR. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol. 2002;13(2):350-8.

185. ElShafie AI, Elghazali G, Rönnelid J, Venge P. Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. Am J Trop Med Hyg. 2006;75(5):864-8.

186. Erlandsen EJ, Randers E, Kristensen JH. Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med. 1998;36(6):393-7.

187. Oliveira AV, Rossi MA, Rogue-Barreira MC, Sartori A, Campos-Neto A. The potential role of Leishmania antigens and immunoglobulins in the pathogenesis of glomerular lesions of hamsters infected with Leishmania donovani. Ann Trop Med Parasitol. 1985;79(5):539-43.

188. Sartori A, Roque-Barreira MC, Coe J, Campos-Neto A. Immune complex glomerulonephritis in experimental kala-azar. II: Detection and characterization of parasite antigens and antibodies eluted from kidneys of Leishmania donovani-infected hamsters. Clin Exp Immunol. 1992;87(3):386-92.

189. Mancianti F, Poli A, Bionda A. Analysis of renal immune-deposits in canine leishmaniasis. Preliminary results. Parassitologia. 1989;31(2-3):213-30.

190. Poli A, Abramo F, Mancianti F, Nigro M, Pieri S, Bionda A. Renal involvement in canine leishmaniasis. A light-microscopic, immunohistochemical and electron-microscopic study. Nephron. 1991;57(4):444-52.

191. Lopez R, Lucena R, Novales M, Ginel PJ, Martin E, Molleda JM. Circulating immune complexes and renal function in canine leishmaniasis. Zentralbl Veterinarmed B. 1996;43(8):469-74.

192. Frank J, Engler-Blum G, Rodemann HP, Muller GA. Human renal tubular cells as a cytokine source: PDGF-B, GM-CSF and IL-6 mRNA expression in vitro. Exp Nephrol. 1993;1(1):26-35.

193. Ramos-Remus C, Sierra-Jimenez G, Skeith K, Aceves-Avila FJ, Russell AS, Offer R, et al. Latitude gradient influences the age of onset in rheumatoid arthritis patients. Clin Rheumatol. 2007;26(10):1725-8.

194. report Un. World Population Prospects: Life expectancy. United Nations Statistics Division, Department of Economic and Social Affairs, Population Division 2012.

195. nation U. Total Fertility rate (Children born per woman). US: Kaiser Family Foundation, 2012.

56

196. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum. 1990;33(12):1770-5.

197. Heliovaara M, Aho K, Reunanen A, Knekt P, Aromaa A. Parity and risk of rheumatoid arthritis in Finnish women. Br J Rheumatol. 1995;34(7):625-8.

198. Spector TD, Roman E, Silman AJ. The pill, parity, and rheumatoid arthritis. Arthritis Rheum. 1990;33(6):782-9.

199. Jacobsen S. Young age of onset is associated with increased prevalence of circulating IgM rheumatoid factor and antinuclear antibodies at presentation in women with rheumatoid arthritis. Clin Rheumatol. 2004;23(2):121-2.

200. Neovius M, Simard JF, Askling J. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis. 2011;70(6):1010-5.

201. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.

202. Lekpa FK, Ndongo S, Tiendrebeogo J, Ndao AC, Daher A, Pouye A, et al. Rheumatoid arthritis in Senegal: a comparison between patients coming from rural and urban areas, in an urban tertiary health care center in Senegal. Clin Rheumatol. 2012;31(11):1617-20.

203. Ouedraogo DD, Singbo J, Diallo O, Sawadogo SA, Tieno H, Drabo YJ. Rheumatoid arthritis in Burkina Faso: clinical and serological profiles. Clin Rheumatol. 2011;30(12):1617-21.

204. Chun-Lai T, Padyukov L, Dhaliwal JS, Lundström E, Yahya A, Muhamad NA, et al. Shared epitope alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)--positive rheumatoid arthritis in three Asian ethnic groups. PLoS One. 2011;6(6):e21069.

205. Peschken CA, Hitchon CA, Robinson DB, Smolik I, Barnabe CR, Prematilake S, et al. Rheumatoid arthritis in a north american native population: longitudinal followup and comparison with a white population. J Rheumatol. 2010;37(8):1589-95.

206. Kanyerezi BR, Baddeley H, Kisumba D. Rheumatoid arthritis in Ugandan Africans. Ann Rheum Dis. 1970;29(6):617-21.

207. Davis P, Stein M, Ley H, Johnston C. Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann Rheum Dis. 1989;48(1):73-6.

208. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N. Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life. Clin Rheumatol. 2012;31(2):329-34.

209. Houba V, Bagg LR, Hansen DP, Bowry T. Rheumatoid arthritis in Kenya. II. Serological observations. Ann Rheum Dis. 1978;37:26-30.

210. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005;64(12):1744-9.

211. Idris AM, Ibrahim YE, Warnakulasuriya KA, Cooper DJ, Johnson NW, Nilsen R. Toombak use and cigarette smoking in the Sudan: estimates of prevalence in the Nile state. Prev Med. 1998;27(4):597-603.

57

212. Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol. 2011;23(2):92-8.

213. Sluis-Cremer GK, Hessel PA, Hnizdo E, Churchill AR. Relationship between silicosis and rheumatoid arthritis. Thorax. 1986;41(8):596-601.

214. Klockars M, Koskela RS, Jarvinen E, Kolari PJ, Rossi A. Silica exposure and rheumatoid arthritis: a follow up study of granite workers 1940-81. Br Med J (Clin Res Ed). 1987;294(6578):997-1000.

215. Hart JE, Laden F, Puett RC, Costenbader KH, Karlson EW. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect. 2009;117(7):1065-9.

216. Yahya A, Bengtsson C, Lai TC, Larsson PT, Mustafa AN, Abdullah NA, et al. Smoking is associated with an increased risk of developing ACPA-positive but not ACPA-negative rheumatoid arthritis in Asian populations: evidence from the Malaysian MyEIRA case-control study. Mod Rheumatol. 2012;22(4):524-31.

217. Jain A, Singh JA. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013;5(3):265-99.

218. Singh U, Vishwanath A, Verma PK, Singh NK, Shukla RC, Singh S, et al. Is rheumatoid factor still a superior test for the diagnosis of rheumatoid arthritis? Rheumatol Int. 2010;30(8):1115-9.

219. Gomez EL, Gun SC, Somnath SD, D'Souza B, Lim AL, Chinna K, et al. The prevalence of rheumatoid factor isotypes and anti-cyclic citrullinated peptides in Malaysian rheumatoid arthritis patients. Int J Rheum Dis. 2011;14(1):12-7.

220. Mikuls TR, Holers VM, Parrish L, Kuhn KA, Conn DL, Gilkeson G, et al. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid arthritis. Arthritis Rheum. 2006;54(9):3057-9.

221. Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, et al. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol. 2010;37(6):1105-12.

222. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci. 1999;318(1):55-60.

223. Gould T, Tikly M, Asherson R, Loizou S, Singh S. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol. 2006;35(1):29-34.

224. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.

225. Bizzaro N, Pregnolato F, van Boekel MA, Villalta D, Tozzoli R, Tonutti E, et al. Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Ann Rheum Dis. 2012;71(8):1388-92.

226. Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum. 2003;48(1):1-5.

227. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient

58

characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46(2):342-9.

228. Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70(9):392-9.

229. Ahmed MM, Obaid Al-Ruhaimi KA, Mohammed SH. Evaluation of the rheumatoid factors of the IgG, IgM and IgA isotypes as prognostic parameters for rheumatoid arthritis among Iraqi patients. Indian J Pathol Microbiol. 2010;53(3):433-8.

230. van Leeuwen MA, Westra J, van Riel PL, Limburg PC, van Rijswijk MH. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol. 1995;24(3):146-53.

231. Winska Wiloch H, Thompson K, Young A, Corbett M, Shipley M, Hay F. IgA and IgM rheumatoid factors as markers of later erosive changes in rheumatoid arthritis (RA). Scand J Rheumatol Suppl. 1988;75:238-43.

232. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58(1):36-45.

233. Mullazehi M, Mathsson L, Lampa J, Ronnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis. 2007;66(4):537-41.

234. Mathsson L, Ahlin E, Sjöwall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjogren's syndrome A antibodies. Clin Exp Immunol. 2007;147(3):513-20.

235. Too CL, Yahya A, Murad S, Dhaliwal JS, Larsson PT, Muhamad NA, et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther. 2012;14(2):R89.

236. Ärlestig L, Mullazehi M, Kokkonen H, Rocklöw J, Rönnelid J, Rantapää-Dahlqvist S. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from Northern Sweden. Ann Rheum Dis. 2012;71(6):825-9.

237. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Rönnelid J, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther. 2011;13(1):R13.

238. Mullazehi M, Wick MC, Klareskog L, von Vollenhoven R, Rönnelid J. Anti-type II collagen autoantibodies are associated with early erosions in rheumatoid arthritis. Arthritis Res Ther. 2012;14(3):R100.

239. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis. 2007;66:537-41.

240. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound anti-type II collagen containing immune complexes induce production of TNF-a, IL-1ß and

59

IL-8 from peripheral blood monocytes via FcgRIIa. A potential patho-physiological mechanism for humoral anti-collagen type II immunity in RA. Arthritis Rheum. 2006;54(6):1759-71.

241. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44(12):1336-40.

242. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al. Validation of a multiplex chip-based for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14(5):R201.

Acta Universitatis UpsaliensisDigital Comprehensive Summaries of Uppsala Dissertationsfrom the Faculty of Medicine 919

Editor: The Dean of the Faculty of Medicine

A doctoral dissertation from the Faculty of Medicine, UppsalaUniversity, is usually a summary of a number of papers. A fewcopies of the complete dissertation are kept at major Swedishresearch libraries, while the summary alone is distributedinternationally through the series Digital ComprehensiveSummaries of Uppsala Dissertations from the Faculty ofMedicine.

Distribution: publications.uu.seurn:nbn:se:uu:diva-204392

ACTAUNIVERSITATIS

UPSALIENSISUPPSALA

2013